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1    Introduction 
Lung cancer, a disease characterized by uncontrolled cell growth in the lungs, is the 
leading cause of cancer deaths for both men and women. Lung cancer was first 
diagnosed in the mid-nineteenth century, when it was considered a relatively rare 
occurrence. By the turn of the century, it was considered the most common 
malignancy and the leading cause of cancer-related death in more than 25 developed 
countries. Lung cancer accounts for almost 28% of all cancer deaths worldwide, with 
a global incidence of this disease rising at approximately 0.5% per year. Lung cancer 
is often fatal, with a 5 year survival rate of ~14%, primarily due to inability to detect 
the disease early. In the European Union, lung cancer accounts for 20% of all cancer-
related deaths. This figure is likely to increase as the population ages and more 
countries join the European Union from Eastern Europe, where smoking rates are 
higher (Bray et al., 2003; Coleman et al., 2003; Quinn et al., 2003; Levi et al., 2004). 
 
1.1    Lung cancer pathology  
1.1.1    Risk factors 
Lung cancer is a complex disease caused by a variety of factors. It involves genetics, 
the immune system, dose and duration of exposure to carcinogens, cellular irritation, 
DNA alteration, and many more factors (Abdel-Rahman et al., 1998; Amos et al., 
1999; Lam et al., 1999). Smoking, particularly cigarette smoking, is the major cause 
of lung cancer, contributing to 70% of lung cancers. Exposure to carcinogens, which 
are present in tobacco smoke, immediately causes small changes to the tissue lining 
the bronchi of the lungs (the bronchial mucous membrane). This effect is cumulative; 
thus, with continued exposure, more tissue gets damaged, until a tumor develops 
(Lam et al., 1999; Rojas et al., 2004). Furthermore, passive smoking, or inhalation of 
another’s exhaled smoke, has recently been identified as a more common cause of 
lung cancer in non-smokers than previously believed (Schwartz et al., 1999). 
However, the incidence of lung cancer deaths not associated with smoking or other 
environmental factors (e.g., asbestos, radon, nickel, and coal tar products) is 
increasing at a higher rate than that of any other group. This effect appears to be 
linked with diet, infection, and inflammatory diseases (Steenland et al., 1997; Jung et 
al., 2000). Numerous studies suggest a correlation between lung cancer and a high 
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intake of cholesterol or incidence of viral or bacterial infections such as Chlamydia 
pneumoniae (Ignacio et al., 1998; Nyberg et al., 1998; Littman et al., 2004). 
 
1.1.2    Pathological processes 
Lung cancer, the final step in a series of morphological and structural changes 
occurring over several years, is caused by carcinogens. These carcinogens affect DNA 
via several molecular mechanisms, producing mutations at multiple sites of the 
epithelial lining of the lung (Roland et al., 1998). These mutations provide the cell 
with a proliferative advantage over nonmutant epithelial cells and promote clonal 
expansion to form a preneoplastic lesion. Lesions, when subjected to further 
mutations, transform into more malignant invasive cancer phenotypes (Lee et al., 
1998; Rubens et al., 2002). 
Mutations causing tumors occur mainly in genes that contain instructions for 
regulating cell growth and differentiation. Both the activation of proto-oncogenes and 
regression of tumor suppressor genes are likely to be the earliest steps in the 
development of lung cancer (Liotta et al., 1991). Proto-oncogenes are important for 
the regulatory mechanisms of growth, cell-cycle control, programmed cell death, and 
terminal differentiation. Abnormal expression of these genes by point mutations, 
translocation, or DNA amplification may confer tumorigenicity. In addition, oncogene 
products, through the gain of function mutations, are positive effectors of 
transformation (Bouck et al., 1990). Overexpression of oncogenes such as K-ras and 
c-Myc was particularly observed in the development of lung cancer (Rodenhuis et al., 
1990; Prins et al., 1993; Lorenz et al., 1994). 
Unlike classical oncogenes, tumor suppressor genes are oncogenic through loss, rather 
than activation of function. The most commonly altered tumor suppressor gene, p53, 
is almost always defective or downregulated in most cases of lung cancer (Halevy et 
al., 1990; Hollstein et al., 1991). 
However, alterations in both oncogenes and tumor suppressor genes instruct the cells 
and their offspring to reproduce at a dramatic rate, without regard for the normal 
shape and function of the lung. This unregulated reproduction causes the formation of 
tumors that may block air passages in the lung. In most cases, tumors arise in the 
bronchial mucosa and invade the bronchial wall. Additionally, tumors may grow 
around the bronchus, subsequently obstructing the bronchial lumen. Obstruction of 
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the lumen leads to collapse and often infection of the lung distal to the tumor (Rubens 
et al., 2002).  
Furthermore, lung cancers can metastasize to remote sites by blood or lymphatics. 
Metastatic spread is a multistep process that distinguishes benign tumors from 
invasive tumors (Chambers et al., 2002). The first site of tumor metastasis is usually 
the lymph nodes within the lungs and the mediastinum; in later stages, tumors can 
spread to virtually any other organ.  
 
 
Figure 1: Sequential pathogenic changes involved in lung cancer: Although multiple genetic 
markers (indicated by the arrows) are abnormal in lung cancers, the timing of their appearance during 
the lengthy preneoplastic process varies. Several alterations have been described in histologically 
normal specimens of bronchial epithelium from smokers. Other changes (such as hyperplasia and 
metaplasia) have been detected in slightly abnormal epithelium and are regarded as early changes. 
Molecular changes, detected frequently in dysplasia, are considered intermediate in timing, whereas 
those usually detected in carcinoma in situ or invasive stages are regarded as late changes (Hirsch et 
al., 2001).  
 
1.2    Classification 
Primary tumors are classified based on their histological appearance and presumed 
tissue of origin: epithelium, lymphatics, mesothelium, soft tissue, or miscellaneous. 
However, mixed tumors exist and are often classified according to the most 
predominant cell type found. 
Tumors derived from epithelium are by far the most common and diverse. Based on 
their morphological appearance, epithelial tumors are further classified into two major 
groups: small and non-small cell lung cancer (Kreyberg et al., 1982; Beadsmoore et 
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al., 2003). Small cell lung carcinoma (SCLC) is the less common form of lung cancer, 
making up 20% of cases. SCLC often starts in the larger breathing tubes and grows 
rapidly. 
Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancer cases 
and is classified into three types: 
• Adenocarcinoma represents the largest number of lung cancers (35%-40%) 
and usually arises in the outlying areas of the lung.  
• Squamous cell cancer represents 25%-30% of lung cancers. It also starts in 
the larger airways but grows slower, meaning that the size of these tumors 
varies when diagnosed. 
• Large cell carcinoma is found in approximately 10%-15% of lung cancer 
cases. It is a fast-growing form that grows near the surface of the lung. 
Other rare types of cancer may be found, although they represent a very small 
percentage (less than 5%) of the total number of lung cancer cases, which includes 
adenosquamous carcinoma, sarcomatoid carcinoma, carcinoid tumor, and salivary-
gland tumors (Travis et al., 2004; Beasley et al., 2005). 
This classification, although based on simple pathomorphological criteria, has very 
important implications for both clinical management and prognosis of the disease. 
 
1.3    Treatment and prognosis 
The prognosis for lung cancer is poor, showing little improvement over the past 
twenty years. Furthermore, small cell lung cancer and non-small cell lung cancer are 
treated in different manners. In essence, the stage of the disease plays a major role in 
deciding these treatment options. 
 
1.3.1    Staging 
As described, treatment for non-small cell lung cancer depends primarily on the stage 
of the cancer. Staging classification is mainly based on the results of pulmonary X-
rays, CT-scans of the thorax and upper abdomen, bronchoscopy, and, in elective 
cases, mediastinoscopy. The classification follows the recommendations from Union 
Internationale Contre le Cancer (UICC) and is first categorized by the size and spread 
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or extension of the tumor, such as relation to main bronchus or thoracic wall, node 
involvement, and metastases (Beahrs et al., 1992; Sobin et al., 1997). This 
identification method is called the TNM system. The TNM system is used to 
determine the stage (numbered 0 to IV) of the tumor. The four stages, based on the 
TNM classification described below, provide a consistent and reproducible 
classification for describing the extent of disease (Mountain et al., 1997; Beadsmoore 
et al., 2003).  
However, the TNM system is not used in the practical management of small cell lung 
cancer, mainly because of the overt metastatic disease often observed at diagnosis in 
the majority of patients. Hence, these cancers are broadly classified into two 
categories: extensive and limited stage disease. Limited stage disease is defined as 
cancer confined to the hemithorax of origin, the mediastinum, and the supraclavicular 
nodes. With extensive stage disease, the tumor is widespread; patients with distant 
metastases are always included in this group (Beadsmoore et al., 2003). 
 
Table 1: International staging system for lung cancer: The tumor, node, metastasis (TNM) 
international staging system for lung cancer, developed by the American Joint Committee on Lung 
Cancer (Mountain et al., 1997). 
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1.3.2    Management 
Depending on the type and stage of the disease, lung cancer can be treated with 
surgery, chemotherapy, radiation therapy, or a combination of these treatments. In the 
absence of treatment, tumor progression in SCLC is rapid, with a median survival of 2 
to 4 months. On the other hand, patients with untreated NSCLC, even some with 
widespread metastatic disease, may, in rare instances, live for 5 years. Thus, the 
therapeutic approaches to these groups of patients should differ. 
 
1.3.2.1    Surgery 
There are three surgical procedures commonly used to treat lung cancer: wedge 
resection, or segmentectomy (in which a small section of the lung is removed); 
lobectomy (in which an entire section is removed); pneumonectomy (which involves 
the removal of an entire lung). Surgery remains one of the main cures for about one 
third of patients with NSCLC (stages I, II, and a limited group of patients with stage 
IIIA) who have surgically resectable disease (Shah et al., 1995; Wada et al., 1996). In 
SCLC, however, surgery is not feasible, since most patients have either locally 
advanced disease or distant metastases. 
 
1.3.2.2    Chemotherapy 
Chemotherapy modestly improves the survival rate of patients whose tumors are 
somewhat more advanced and can also provide symptomatic relief. A program of 
chemotherapy before surgery produces objective tumor responses in about 80% of 
patients with SCLC, while response rates in NSCLC are lower and often incomplete, 
as approximately 70% of NSCLC tumors are unresectable at the time of diagnosis 
(Feigal et al., 1993). New drugs like taxanes (paclitaxel and docetaxel), camptothecins 
(topotecan and irinotecan), new anti-metabolites (such as gemcitabine and 
difluorodeoxycytidine), and anti-tubulin agents (vinorelbine) show promise in the 
management of NSCLC (Halme et al., 1997; Mattson et al., 1997; Giaccone et al., 
1998). 
 
1.3.2.3    Radiation therapy 
When surgery is not the best option, 3D conformal radiation therapy system delivers 
the highest possible radiation dose targeted directly at the tumor. This method spares 
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normal tissues and reduces damage to other organs in the chest. Therefore, patients 
with tumors too extensive for surgery and without distant metastases are likely to 
benefit from radiotherapy. Radiotherapy elicits responses in about 90% of patients 
with SCLC and in about 50% of those with NSCLC (Noordijk et al., 1988; Stewart et 
al., 1998). 
 
1.3.2.4    Combined modality therapy 
Clinical trials and meta-analyses demonstrated that combination therapy with both 
chemotherapy and radiotherapy improves the therapeutic outcome in patients with 
locally advanced, unresectable stage III NSCLC over a single modality therapy 
(Taillade et al., 2004; Pritchard et al., 1996). Combined modality therapy given to 
these patients increased the median survival to 14 months and the 5 year survival rate 
to 20%, nearly three times that reported with radiation therapy alone (Roth et al., 
1998). Combination chemotherapy with etoposide/cisplatin prolongs survival and is 
well-tolerated among SCLC patients, particularly patients with limited disease 
(Pignon et al., 1992; Arriagada et al., 1994). 
 
1.3.2.5    Targeted therapy 
The limited success of classic chemotherapeutic agents has led researchers to focus on 
developing rationally targeted therapies aimed at the molecular mechanisms 
underlying lung tumorigenesis. Agents inhibiting various aspects of tumor protein 
trafficking and protein degradation, cell cycle regulation, angiogenesis, and 
antigenicity are currently under clinical investigation. For example, Tarceva™ 
(erlotinib)-an epidermal growth factor receptor (EGFR) blocker, in combination with 
a Celebrex® (celecoxib)-an anti-inflammatory medication, is currently under phase II 
trial for the treatment of stage IV disease lung cancer patients (Perez-Soler et al., 
2004).  
In addition, the existence of hypoxia and necrosis also allows use of tumor-selective 
therapy in regions resistant to both chemotherapy and radiotherapy. Hypoxia (very 
low oxygen concentrations) in tumors is a consequence of insufficient vascularization, 
impaired microcirculation, and thus increased diffusion distances, subsequently 
leading to necrosis and tumor cell death (Dang et al., 1999; Hockel et al., 2001). To 
counteract the possible deleterious effects of hypoxia, an immediate molecular 
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response is initiated, causing adaptation responses aimed at cell survival (Bunn et al., 
1996). This response is mediated by the hypoxia-inducible factor-1 (HIF-1), a 
heterodimer consisting of an α- and a β-subunit. HIF-1α protein, which is stabilized 
under hypoxic conditions, dimerizes with HIF-1β and transactivates target genes, 
including genes related to cell proliferation, cell survival, apoptosis, angiogenesis, 
vascular tone regulation, energy metabolism, oxygen transport, cell adhesion, and cell 
motility (Semenza et al., 1992, 1996; Wang et al., 1995). Several HIF-responsive 
genes are upregulated in human malignancies (Zhong et al., 1999; Talks et al., 2000). 
The role of HIF-dependent gene expression in tumor growth was well-demonstrated, 
but the correlation between HIF-1α overexpression and adverse clinical outcome of 
specific tumor disease is not identical. Overexpression is associated with both 
increased and decreased mortality (Semenza et al., 2003). Controversial reports 
abound concerning the role of HIF-1 pathway in lung cancers. We address this issue 
in a mouse model of adenocarcinoma, a common form of lung cancer. 
 
1.3.2.6    Immunotherapy 
Host defense mechanisms may play an important role in diminishing tumors. Defects 
in immune response in patients with a variety of tumors and in tumor-bearing animals 
have been well-documented. In addition, several features of tumor cells may also limit 
the effectiveness of immune stimulation (Boon et al., 1997; Gilboa et al., 1998; 
Timmerman et al., 1999; Rosenberg et al., 2001) that includes active ‘tolerance’ of T- 
cells, resulting from an inadequate presentation of tumor associated antigens (TAAs) 
on the tumors. 
Two different cell-based immunomodulatory strategies to improve the presentation 
and effectiveness of TAAs against tumors have been investigated. The first strategy 
involves antigen presenting cells, modified to either present specific tumor antigens to 
immune effector cells or to be more efficient in eliciting an anti-tumor immune 
response. A second strategy involves genetic modification of T-cells to alter their 
antigen specificity and increase their responsiveness to tumor antigens. 
Dendritic cells (DCs) are the most efficient antigen presenting cells. They induce 
activation and proliferation of both naive CD8+ cytotoxic T lymphocytes (CTLs) and 
CD4+ T-helper (Th) cells, generating an anti-tumor response. (Porgador et al., 1995; 
Brossart et al., 1997; Ohshima et al., 1997; Shen et al., 1997; Nair et al., 1998). Lack 
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of tumor antigen presentation by DCs in vivo might prevent the host immune system 
from eradicating most immunogenic tumors (Schuler et al., 1997). Increasing 
evidence indicates that dendritic cells, pulsed with specific tumor antigen peptides or 
tumor extracts in an attempt to load tumor peptides into the major histo- compatibility 
complex (MHC) for presentation to T-cells, encourage a more potent anti-tumor 
response. However, these methods suffer from drawbacks such as transient 
presentation to single, known TAAs.  
Considering the heterogeneous expression and undefined nature of TAAs, other Ag 
presentation systems have been developed to stimulate polyclonal immune responses 
against multiple tumor associated proteins by co-culturing DCs with attenuated tumor 
cells, tumor lysates, or transfecting with tumor derived RNA (Boczkowski et al., 
1996; Nair et al., 1997, 1998; Celluzzi et al., 1998; Nestle et al., 1998) or fusion with 
tumor cells. However, fusion of tumor cells and DCs are most efficient in inducing a 
host T cell-mediated anti-tumor response. This is most likely due to the expression of 
MHC class I and class II antigens, as well as co-stimulatory molecules, on the DC-
tumor cell chimera. However, the efficiency of fusion hybrids in eliciting tumor 
specific immune responses against lung carcinomas has not yet been demonstrated. 
 
1.4    Animal models of lung cancer 
Late diagnosis and inadequate knowledge about tumor progression and its associated 
molecular alterations pose significant problems in the treatment of lung cancer 
patients. To this end, appropriate and evolving animal models that mimic human 
disease paradigm in terms of genetic alterations and histological characteristics should 
be developed. Such experiments have been performed largely on mice, which could 
safely replace the more costly and time-consuming large animal studies in dog and 
monkey models. Because they readily mimic human lung cancers, mouse models 
facilitate the development of novel therapeutic approaches and methods for early 
diagnosis. To date, several approaches have been taken in the development of murine 
lung cancer models. 
 
1.4.1    Spontaneous tumor models 
Spontaneous and carcinogen induced tumors are either idiopathic or arise following 
carcinogenic or viral exposure in sensitive mouse strains such as A/J and SWR to 
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mimic the clinical situation most closely (Tuveson et al., 1999). However, due to 
significant obstacles to the use of such model systems, new models must be developed 
for widespread use in experimental therapeutics.  
 
1.4.2    Transplantable animal tumor models 
1.4.2.1    Xenograft model 
Early passages of transplanted tumors most closely resemble spontaneous cancer. 
These tumors can be transplanted into mice via various routes: subcutaneous, 
intraperitoneal, intratracheal, or intravenous, each with specific advantages and 
limitations (McLemore et al., 1988; Gazdar et al., 1997). These early passages show 
significant heterogeneity in cell kinetics and histology. Despite these changes, the 
majority of xenografted human tumors maintain the morphologic and biochemical 
characteristics of their original tumors. In fact, strong correlations can be made 
between average growth delay for human tumors in immunodeficient mice treated 
with the best available drug combinations and complete clinical response rates 
(Giovanella et al., 1983). In increasing order of responsiveness, these correlations 
have been shown for human xenografts of non-small cell lung cancer, colon cancer, 
breast cancer, and malignant melanoma. 
 
1.4.2.2    Orthotopic xenograft model 
The orthotopic xenograft model is another transplanted system in which tumor cells 
are implanted at the site of the organ of origin. This organ-specific site presumably 
provides the tumor cells with an optimal environment for growth and progression and 
may reflect the clinical situation most closely. However, this model yields a high 
mortality rate (Jerald et al., 1999; Tuveson et al., 1999). 
 
1.4.3    Genetically engineered animals 
Many different genetically engineered mouse models for lung cancer have been 
developed to identify the role of specific genes during transformation and disease 
progression. Constitutive or conditional transgenes can be targeted to the lung to 
regulate the expression and ablation of genes. This allows the generation of animal 
models that represent a better paradigm for cancer development than the widely used 
xenograft model. This technology, however, is limited by the number of tools 
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available to direct these genetic events to many of the cell types clinically important 
for lung cancer (Kwak et al., 2004).  
On the other hand, the development of mouse models is complicated by the cellular 
diversity of lung cancer. Therefore, the success of establishing mouse models for lung 
cancer will depend upon the ability to target the specific oncogenic genetic 
modification in a cell-specific fashion. We attempted to establish orthotopic xenograft 
mouse models for adenocarcinoma and lewis lung carcinomas in order to study the 
underlying molecular mechanisms, to develop novel therapeutics, and to develop 
methods for early detection. 
 
1.5    Imaging techniques 
Another significant problem in the treatment of lung cancer patients is late diagnosis. 
Unfortunately, the 5-year survival rate for lung cancer ranges between 5%-10%, 
primarily because most patients are diagnosed with advanced-stage disease. However, 
when lung cancer is diagnosed and resected at an early stage, the survival rate may be 
as high as 80%. 
Nevertheless, a group of new techniques known collectively as “molecular imaging” 
now offers scientists an unprecedented opportunity to significantly improve the 
detection of localized lung cancer, better understand tumor biology, improve 
diagnosis, enhance treatment, and consequently reduce mortality. These imaging 
modalities explore the utility of spiral computed tomography (CT), high magnetic 
field magnetic resonance imaging scanners (MRI), PET imaging, fluorescence 
bronchoscopy, and the proteomic and genomic analysis of tumors and other 
specimens. These approaches (in particular, the application of CT) have the potential 
to identify small and early lesions that have not been readily detectable in clinical 
practice through more conventional methods.  
Helical or spiral CT is a radiographic method that can provide within short scanning 
times high quality, three-dimensional images of the lungs and lung nodules during a 
single breath-hold. Helical CT is more sensitive than chest x-ray and can often detect 
lung nodules as small as 5mm in diameter in humans. However, the resolution of 
conventional CT-systems is not sufficient for scanning and quantitative monitoring of 
lung disease in small animal models. Furthermore, the CT technique suffers from poor 
soft tissue resolution, though visualization of the lung tissue means imaging in high 
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contrast. The recent development of high resolution CT imaging such as of micro 
computed tomography (µCT) has not solved the problem of poor contrast; however, 
the higher resolution makes the technique suitable for small animal imaging. Micro-
CT systems provide resolution down to 10 µm, but there is a trade-off between 
resolution, field of view, and radiation dose.  
The successful development of tumor models with human cell lines and the 
availability of novel therapeutic approaches like anti-angiogenic or genetic therapies 
increase the need for advancement in high resolution in vivo imaging in small animal 
models for tumor screening and volumetry. Beyond morphology at a definite time-
point, follow-up studies play a critical role in cancer research. Therefore, imaging 
systems offering a high resolution in time and space have to be provided. The 
applicability of high resolution Magnetic Resonance Imaging (MRI) systems for this 
purpose has been already demonstrated. Long acquisition times and limitation to a 
small field-of-view dependent on the required resolution disqualify the system for 
quantitative and longitudinal monitoring of small lung nodules. 
In this context, we introduced the novel high resolution micro-computed-tomography 
(µCT) and flat-panel volumetric Computed Tomograph (fpvCT) for in vivo small 
animal imaging to gain novel insights into lung tumor evolution and processes and to 
monitor therapeutic effects. 
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2. Aims 
 
This thesis was guided in its formation by the following goals. 
 
• Establishment of lung mouse tumor models.  
• Analysis of the role of HIF-1α in the adenocarcinoma mouse model.  
• Study of tumor regression capabilities by dendritic/tumor cell hybrid-
primed T-lymphocytes and hybrid vaccination in a lewis lung carcinoma 
model. 
• Application of new imaging strategies in order to monitor tumorogenesis 
and tumor metastasis in vivo over time (multislice computed tomography, 
micro-computed tomography, and flat-panel volumetric computed 
tomography). 
• Use of the imaging techniques to delineate vessel architecture 
(vascularization) and blood supply of lung tumors. 
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3    Materials and Methods 
3.1    Cell biological methods 
3.1.1 Culture of human A549, mouse LLC1 and mouse B16/F10 cells 
 
LLC1-mouse lewis lung carcinoma, B16/F10-mouse melanoma, and A549-human 
lung adenocarcinoma cell lines were obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA).  
LLC1 cells were maintained in RPMI-1640 medium supplemented with 2% FBS, 
penicillin (100 U/ml), and streptomycin (0.1 mg/ml) at 37°C in humidified 
atmosphere containing 5% CO2.  
B16/F10 cells were maintained in DMEM/F12 medium supplemented with 10% FBS, 
penicillin (100 U/ml), and streptomycin (0.1 mg/ml) at 37°C in humidified 
atmosphere containing 5% CO2. 
A549 cells were maintained in DMEM/F12 medium supplemented with 10% FBS, 
penicillin (100 U/ml), streptomycin (0.1 mg/ml), 1% MEM vitamin solution, 2 mM 
glutamate and 1% non-essential amino acids at 37°C in humidified atmosphere 
containing 5% CO2. 
RPMI-1640 and DMEM/F12 media were purchased from PAN Biotech GmbH 
(Aidenbach, Germany). FBS was obtained from Greiner BioOne (Frickenhausen, 
Germany). Penicillin, streptomycin, MEM vitamin solution, glutamate, and non-
essential amino acids all were purchased from Gibco (Eggenstein, Germany). 
 
3.1.2    Cell culture and generation of HIF-1α overexpressing cells 
A549 cells were transfected with pMG-HIF-1α or empty pMG plasmid (as control) 
with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for 6 h according to the 
manufacturer’s recommendations. Cells were treated with medium containing 750 
µg/ml hygromycin B (Roche, Indianapolis, IN, USA) 24 h post-transfection. The 
medium containing hygromycin B was replaced every 48 h for two weeks. After two 
weeks, the concentration of hygromycin B was reduced to 500 µg/ml, and incubation 
was continued for two more weeks. Ultimately, cells were maintained continuously in 
350 µg/ml hygromycin B (Goyal et al., 2004).  
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3.1.3    Hypoxia treatment 
A549 cells were exposed to hypoxic conditions in a chamber equilibrated with a 
water-saturated gas mixture of 1% (v/v) oxygen, 5% (v/v) carbon dioxide, and 94% 
(v/v) nitrogen at 37oC. Control cells were maintained under normoxic conditions in 
water-saturated room air, supplemented with 5% (v/v) carbon dioxide at 37oC.  
 
3.1.4    Immunocytochemistry of HIF-1α 
The A549 cells selected for hygromycin resistance were grown on chamber slides and 
treated as indicated. Cells were removed and fixed immediately in acetone:methanol 
(1:1). The fixed cells were incubated overnight at 4°C in 100 µl phosphate-buffered 
saline (PBS; Gibco, Eggenstein, Germany) containing an anti-human HIF-1α mouse 
monoclonal antibody clone 54 (1:100, BD Biosciences, Heidelberg, Germany). 
Indirect immunofluorescence was conducted by incubation with fluorescein 
isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG antibodies (1:100, DAKO, 
Glostrup, Denmark) in 100 µl PBS. Coverslips were mounted on glass slides and 
subjected to microscopic analysis (Hanze et al., 2003). 
 
3.1.5    Hypoxia-responsive element reporter gene assay  
A dual reporter gene assay for studying HIF-1α dependent gene regulation was 
performed. One vector, carrying a firefly luciferase gene and controlled by a three-
tandem repeat of the HRE coupled to a thymidine-kinase minimal promoter (TK-MP) 
from Herpes simplex, was co-transfected with a second reporter vector carrying a 
renilla luciferase gene controlled by the TK-MP promoter without HRE. The values 
represent the ratio of chemiluminescence measured for firefly and renilla, 
respectively, thus giving the HRE specific luciferase activation. Hypoxic-responsive 
promoter constructs were prepared as previously described (Goyal et al., 2004). The 
HRE-TK-MP and pRL-TK-MP plasmids were transfected in a molar ratio of 3:1 into 
A549 cells by Lipofectamin 2000 according to the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA, USA) in a 48-well plate. Transfected cells were incubated 
for 6 h in FCS-containing medium and then replaced by serum-free medium for 24 h 
in normoxic and hypoxic conditions. The cells were lysed in 4°C luciferase lysis 
buffer (Promega, Mannheim, Germany), and firefly and renilla luciferase activities  
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were measured by a bioluminometer (TEKAN, Crailsheim, Germany) (Hanze et al., 
2003; Goyal et al., 2004). 
 
3.1.6  Determination of vascular endothelial growth factor (VEGF) concentration 
Subconfluent A549 cells, selected for hygromycin resistance, were grown in 100-mm 
petri dishes with 10 ml of fresh medium for 24 h, either under normoxic or hypoxic 
conditions, as in 3.1.3 methods section. Cell supernatants were collected, clarified by 
centrifugation at 2000 rpm for 5 min, and stored at -20°C. Concentrations of VEGF in 
supernatants were determined with an ELISA kit (R & D Systems, Minneapolis, MN, 
USA) following the manufacturer’s guidelines. Samples were analyzed in duplicate, 
human recombinant VEGF165 diluted in series and used as a standard. VEGF 
concentrations were measured according to the standard curve. Concentrations were 
calculated using a standard curve generated with specific standards provided by the 
manufacturer. The VEGF concentration was expressed as pg of VEGF/ml of medium, 
and per mg of total protein.  
 
3.1.7    MTT assay 
The MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was 
performed to evaluate the effects, if any, of hypoxia and normoxia on A549 cell 
viability and density, as in Section 3.1.3. Cells (2 × 103) were seeded in 96-well plates, 
and the medium was replaced by a fresh serum-free medium. Cells were then exposed 
to hypoxic or normoxic conditions for 1, 2, 4, 6, and 8 days. At the end of this period, 
0.2 mg/ml MTT (Roche, Mannheim, Germany) was added to each well, and 
incubation continued for 1-2 h at 37°C. The extent of MTT reduction to formazan 
within cells was quantified spectrophotometrically (TEKAN, Crailsheim, Germany) at 
490 nm and taken as an indicator of cell viability.  
 
3.1.8    Thymidine incorporation  
Cells were incubated in a serum-free medium in the presence of 3H-thymidine 
(Amersham Pharmacia Biotech UK Ltd., Buckinghamshire, England) (1.5 µCi/100 
µl) for 18 h. After aspiration of unincorporated extracellular tracer, cells were washed 
extensively and incubated in ice-cold 5% (v/v) trichloroacetic acid (TCA; Sigma,  
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Deisenhofen, Germany) for 30 min. After the removal of TCA, cells were lysed with 
0.5 M NaOH. Finally, cells were removed from the wells and resuspended in 5 ml of 
scintillation mixture (Roth, Karlsruhe, Germany) for radioactive counting. Vials were 
vortexed thoroughly before radioactive counts were measured by scintillation counter 
(Canberra Packard, Dreieich, Germany). Counts were measured in dpm 
(disintegrations per minute). 
 
3.1.9    Soft- agar colony-formation assay 
Anchorage-independent proliferation was examined using soft agar (Barr et al., 2000). 
Cells (1 × 104/well) were suspended in 200 µl of 0.35% (v/v) agar in DMEM/F12 
medium supplements with 10% (v/v) FCS, penicillin-streptomycin, L-glutamine, and 
hygromycin B, layered above 200 µl of 0.7% (v/v) agar, and overlaid with 200 µl in 
24-well plates. Six plates were incubated at 37°C for 2 to 3 weeks and imaged by light 
microscopy (20X magnification) in three different non-overlapping views to detect 
colonies. A colony was defined as a group of more than 15 cells.  
 
3.1.10    Generation of bone marrow derived dendritic cells 
Erythrocyte-depleted C57/BL6 mouse bone marrow cells flushed from marrow 
cavities of femurs and tibias were cultured in RPMI-1640 medium supplemented with 
1000 U/ml of both GMCSF (Pepro Tech EC Ltd., London, England) and IL-4 
(Strathmann Biotec AG, Hamburg, Germany) and 100 µg/ml of FLT3 (Pepro Tech 
EC Ltd., London, England) (van den Broeke et al., 2003). On day 6, non-adherent 
cells were collected and replated in new petri dishes with RPMI-1640 medium 
supplemented with 10 µg/ml LPS (Sigma, Deisenhofen, Germany). On day 10, these 
non-adherent cells were removed and stained with anti-mouse CD11c monoclonal 
antibody clone HL3 (1:100; Pharmingen, Heidelberg, Germany) for confirmation of 
DC phenotype.  
 
3.1.11    DC/ Tumor fusion cell preparation 
Fusion of bone marrow derived DCs and LLC1 cells were performed as previously 
described with slight modifications (Banat et al., 2004). DCs were stained red using 
PKH-26-Gl, and tumor cells (LLC1 cells) were stained green using PKH-67-GI  
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fluorescent cell linker kits (Sigma, Deisenhofen, Germany) according to the 
manufacturer’s instructions. After removing the unbound dye, LLC1 cells were 
transferred into an electroporation cuvette and pulsed at 200 V/cm and 200 µs using a 
Gene Pulser (BioRad, Hercules, CA, USA). Treated LLC1 cells and DCs were then 
mixed at a ratio of 2:1 and incubated in serum-free RPMI-1640 medium containing 
50% polyethylene glycol (PEG; Sigma, Deisenhofen, Germany) by stirring for 2 min. 
An additional 7 ml of serum-free RPMI-1640 medium was added to the cell 
suspension over the next 3 min with continued stirring. Then, the cells were washed 
and resuspended in serum-free RPMI-1640 medium and incubated at 37°C in a 
humidified atmosphere (5% CO2). 
 
3.1.12    Fusion efficiency and fluorescence-activated cell sorting 
After 48 h of culture, fusion efficiency was assessed by fluorescence microscopy. 
LLC1 cells revealed green fluorescence; DCs, red fluorescence; and LLC1/DC fused 
cells (Hybrids) showed yellow fluorescence. Fusion hybrids demonstrated viability 
over 90%, as documented by lack of propidium iodide uptake. 
Fusion efficiency was also determined by counting the proportion of double stained 
cells. In addition, cells were also analyzed for fusion efficiency by labeling with 
CD11c, B7.1 and MHC class II. After 48 h of culture, fused mixtures were collected 
and resuspended in PBS (PAA Laboratories GmbH, Linz, Austria) at a concentration 
of 1 x 106 cells/ml for sorting. Hybrid cells (dual color) were gated and sorted using 
fluorescence-activated cell sorting (FACS) Calibur (Becton Dickinson, Heidelberg, 
Germany). The sorted cells, displaying both green and red fluorescence, were 
harvested and resuspended in medium for in vitro and in vivo assays.  
 
3.1.13    Proliferation assay for spleen and lymph node cells 
Spleens and lymph nodes were excised, pushed through fine gauze, and freed from 
debris and dead cells by Ficoll Hypaque density-gradient centrifugation (Amersham 
Pharmacia Biotech, Freiburg, Germany). Isolated spleen cells (SC) and lymph node 
cells (LNC) (1 x 105 cells/well) were seeded onto 96-well round bottomed 
microplates. Irradiated LLC1 cells, syngeneic purified fusion Hybrids, syngeneic 
DCs, mixture of syngeneic DC/LLC1 cells, syngeneic DC/LLC1 lysate or allogeneic 
lymphocytes (Balb/c) were added as stimulator cells at 1 x 104 cells/well in triplicates.  
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The final volume of each well was adjusted to 200 µl with complete medium. 
Triplicate wells of lymphocytes or stimulator cells alone were used as background 
controls. Cells were assessed for incorporation of tritiated thymidine (3H-TdR) on 
days 3 and 5 of culture by adding 37 kBq/well. After 6 h, the cells were harvested 
onto glass filters, and ß-emission was counted using a scintillation counter (Canberra 
Packard, Dreieich, Germany). The results were expressed as mean counts per minute 
(cpm) x103 ± SD of triplicate cultures. Proliferative activity is displayed as a 
proliferation index (radioactivity (cpm)) in test wells divided by that in control wells 
containing responder cells only (Banat et al., 2001).  
 
3.1.14    Cytotoxic assays for spleen and lymph node cells 
Isolated SC/LNC lymphocytes were co-cultured with irradiated LLC1 cells, syngeneic 
purified fusion hybrids, allogeneic T lymphocytes (Balb/c), or syngeneic B16/F10 
tumor cells as targets in various ratios. Cytotoxicity was measured in vitro using the 
standard cell dilution analysis method (Pechhold et al., 1994). Briefly, K562 (human 
chronic myeloid leukemia in blast crisis) cells were obtained from the German 
Collection of Microorganisms and Cell Cultures (DMSZ, Braunschweig, Germany) 
and stained with PE-conjugated anti-human CD13 mouse monoclonal antibody clone 
WM15 and anti-human CD33 mouse monoclonal antibody clone WM53 (1:100, 
Pharmingen, Heidelberg, Germany) were fixed in PBS containing 4% 
paraformaldehyde (PFA; Merck, Darmstadt, Germany) and used as fixed standard 
cells (SC). Aliquots of T lymphocytes/target mixture were stained after 4, 12, or 16 h 
of culture in v-shaped 96-well plates with FITC-conjugated anti-mouse CD4 rat 
monoclonal antibody clone GK1.5, anti-mouse CD8 rat monoclonal antibody clone 
53-6.7, anti-mouse CD16/CD32 rat monoclonal antibody clone 2.4G2, and anti-mouse 
NK1.1 mouse monoclonal antibody clone PK136 (1:10, all from Pharmingen, 
Heidelberg, Germany) for 30 min. After washing, the cells were resuspended in 100 
µl standard cell dilution analysis (SCDA) buffer, consisting of PBS supplemented 
with 1% BSA (Sigma, Deisenhofen, Germany), 105 fixed SC, and 0.2 µg/ml 
propidium iodide. Cells were then analyzed immediately by flow cytometry. Absolute 
cell numbers were determined by the linear correlation between stained T 
lymphocytes, unstained target cells, and the absolute number of SC per sample.  
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Percentage cytotoxicity was calculated according to the formula: % cytotoxicity =1-
LLC1a/SCa X SCb/LLC1b X 100, where LLC1a are propidium iodide negative LLC1  
cells in the effector-target co-culture, SCa are standard cells in the effector-target co-
culture, SCb are standard cells in the LLC1/SC control, and LLC1b are propidium 
iodide negative LLC1 cells in the LLC1/SC control.  
 
3.2    Animal studies 
3.2.1    Animals 
Female C57/BL6 (H-2b), female BALB/c (H-2d), and male immunodeficient CD-1 
nu/nu mice aged 3–5 weeks were purchased from Charles Rivers, Sulzfeld, Germany, 
kept under pathogen-free conditions, and handled in accordance with the European 
Communities recommendations for experimentation.  
 
3.2.2    Tumorigenicity in nude mice  
Tumorigenicity was assessed by subcutaneous injection of A549 cells (2.5 × 106 
cells/200 µl in saline) into 4-week-old male CD-1 nu/nu male mice. The size of the 
tumor was measured using digital calipers (Mitutoyo, Tokyo, Japan). The tumor 
volume (TV) was calculated by the formula: TV (mm3) = (L × W2)/2, where L is the 
longest dimension of the tumor (in mm), and W is the shortest dimension of the tumor 
(in mm). After 8 weeks, the mice were sacrificed, and tumors were prepared and 
embedded in tissue tek (Tissue Tek; Sakura, Torrance, CA, USA) and stored at –80 
°C.  
 
3.2.3    Immunization  
C57/BL6 mice were immunized twice in a 1-week interval by intra-footpad injection 
of 2 x 105 irradiated (6,000 Rad) LLC1, DCs, DC/LLC1, DC/LLC1 lysate, Hybrids or 
PBS alone. Irradiation of cells was performed using irradiator OB 29 (STS GmbH, 
Braunschweig, Germany). Four days after the final immunization, each group of mice 
was injected subcutaneously with 1 x 106 viable LLC1 cells/mouse. Tumor growth 
and survival time were recorded for each group of ten mice. Mice were inspected 
weekly for tumor growth. Size of the tumor was measured as described in Section  
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3.2.2. After 4 weeks, mice were sacrificed, and SC/LNCs were isolated as in 3.1.13 
and taken for proliferation and cytotoxicity assays. 
 
3.2.4    Pre tumor challenge 
C57/BL6 mice were immunized intra-footpad twice in 2-week intervals with 2 x 105 
irradiated LLC1, DCs, DC/LLC1, DC/LLC1 lysate, Hybrids or PBS alone. One week 
after the final immunization, each group of mice was injected subcutaneously with 1 x 
106 viable LLC1 cells/mouse. Tumor growth and survival time were recorded for each 
group of ten mice. Mice were inspected weekly for tumor growth. Size of the tumor 
was measured as described in Section 3.2.2. After 4 weeks, mice were sacrificed, and 
SC/LNCs were isolated as in 3.1.13 and taken for proliferation and cytotoxicity 
assays. 
 
3.2.5    Vaccine therapy 
For post tumor therapy, 1 x 106 LLC1 cells were injected into C57/BL6 mice 
subcutaneously. On days 7 and 14, tumor-bearing mice were treated with 2 x 105 
irradiated LLC1, DCs, DC/LLC1, DC/LLC1 lysate, Hybrids or PBS alone per mouse. 
Tumor growth and survival time were recorded for another 2 weeks. After these 2 
weeks, mice were sacrificed and SC/LNCs were isolated as in 3.1.13 and taken for 
proliferation and cytotoxicity assays.  
 
3.2.6    Adoptive immunotherapy 
For therapy of LLC1 tumors, C57/BL6 mice were injected subcutaneously with 1 x 
106 LLC1 cells/200 µl in saline to initiate tumor formation. Four days after tumor 
inoculation, mice were randomly divided into several groups to intravenously receive 
1 x 107 spleen and lymph node cells, obtained from irradiated LLC1, DCs, DC/LLC1, 
DC/LLC1 lysate, Hybrids or PBS alone immunized and re-immunized mice. On day 
12, mice from each group received a booster-dose of primed T-lymphocytes. Tumor 
growth and survival time of each group of mice were monitored and recorded on a 
regular basis for 4 weeks after tumor inoculation. After these 4 weeks, mice were 
sacrificed, and SC/LNCs were isolated as in 3.1.13 and taken for proliferation and 
cytotoxicity assays. 
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3.2.7    Intratracheal instillation 
Sub-confluent LLC1 cells were treated with trypsin and EDTA (Gibco, Eggenstein, 
Germany) and resuspended in saline. For intratracheal instillation of cells, C57/BL6 
mice were anaesthetized by intraperitoneal injection of a mixture containing 100 
mg/ml ketamine (Ketavet®; Pharmacia & Upjohn, Erlangen, Germany) and 2% 
xylazine (Rompun®; Bayer, Leverkusen, Germany). Later, mice were suspended in a 
hanging position by a rubber band fixed to the incisor teeth of the upper jaw. The 
trachea was intubated via the oral cavity. A Vasocan® Braunüle® 20 G 1 ¼‘‘ (Braun 
Melsungen AG, Melsungen, Germany) tube was placed in the trachea, and the cells (1 
x 106/0.1 ml saline) or saline were instilled into the lungs. Next, the mice were placed 
on a 37°C hot plate for 10-15 min to maintain temperature. Lung tumor growth was 
monitored and confirmed by using both fpvCT and Hematoxylin and Eosin (H&E) 
staining. For histological analysis, lung tissues were fixed in 4% formalin and 
embedded in paraffin. Three µm thick paraffin sections were stained with hematoxylin 
and eosin. 
 
3.2.8    Infusion of fluorescent microspheres 
After confirmation of tumor growth with fpvCT, animals were anesthetized as in 
3.2.7. A polyethylene catheter was positioned either in the right ventricle, left 
ventricle, or in both ventricles, and infused with fluorescent microspheres to trace 
pulmonary and systemic blood flow (Wu et al., 1988; Iwamaru et al., 2001; Iwamaru 
et al., 2003). Because the capillaries were 4-9 µm in diameter, 10 µm yellow and red 
fluorescent microspheres (Molecular Probes Inc., Eugene, OR, USA) were selected 
and diluted to the desired concentration with saline. Certofix Mono Complete Size 1 
catheter (Braun Melsungen AG, Melsungen, Germany) was used for infusion. 1.5 x 
105 yellow fluorescent microspheres (200 µl) were introduced into the right ventricle 
to trace pulmonary blood flow, and systemic blood flow was monitored with 1.5 x 105 
red fluorescent microspheres (200 µl) introduced into the left ventricle. After the 
infusion of fluorescent microspheres, the catheters were flushed with saline containing 
25000 IU/5 ml Heparin sodium (Roche, Mannheim, Germany). Later the animals 
were divided into two groups. One set of animals (n=12) was taken for histological  
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examination and the other set (n=12) for extraction and counting the number of 
fluorescent microspheres.  
 
3.2.9    Tumor and lung tissue digestion and processing 
After fluorescent microsphere infusion, lungs and tumors were separated under light 
microscopic view (Leica Instruments, Nussloch, Germany). Their wet weights and 
volumes were measured, and their digestion was performed as previously described 
(Iwamaru et al., 2001; Iwamaru et al., 2003). Lungs and lung tumors were separately 
placed into polypropylene tubes and digested with 7 ml of a 4 M KOH solution 
containing 0.05% Tween 80, in a water bath at 65°C until the tissue was completely 
dissolved. Homogenous samples were centrifuged (20 min, 2000 g), and the 
supernatant was drawn off, leaving < 1 ml behind. Left over pellet, containing 
fluorescent microspheres and some debris, was rinsed with 9 ml of 0.25% Tween 80 
in demineralized water at 65°C, and centrifuged again at the same force and duration. 
After a final rinsing with demineralized water, the pellet was re-suspended in saline 
and analyzed for the number of fluorescent microspheres using a hemocytometer and 
fluorescent microscope as described in the FMRC manual (Fluorescent Microspheres 
Resource Center, University of Washington, WA, USA) (Bernard et al., 1996). 
 
3.3    Imaging techniques 
3.3.1    Flat-panel volumetric computed tomography 
The flat-panel volumetric Computed Tomography (fpvCT) is a novel high resolution 
Computed Tomography (CT) system developed by General Electric (GE Global 
Research, Niskayuna, NY, USA). In contrast to clinical CT scanners, in the fpvCT, an 
amorphous silicon flat-panel detector is irradiated by a cone-shaped X-ray beam. 
Animals were anaesthetized as in 3.2.7. The mice were mounted on a patient table, 
which was moved into the gantry bore during the scan, while the x-ray tube and 
detector, mounted on a rotating gantry and rotated around the table. The scan was 
performed in a sequential rather than a helical mode. For our investigation, 120 kVp 
at 40 mA was used. The scanning time for one rotation was 8 seconds, covering a 
field-of-view of 4.2 cm in the z-direction, sufficient for scanning the thorax of one 
mouse. Projection images were reconstructed using a cone-beam algorithm and an 
edge-defining reconstruction kernel (Kalender et al., 2003; Kiessling et al., 2004).  
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Data can be reconstructed at arbitrary voxel sizes, but (0.05 mm)3 isotropic voxels 
were used for this investigation. All data were transferred to an Advantage Windows 
Workstation 4.1 (GE Healthcare Europe, Buc, France) and processed with the Volume 
Rendering Software. 
 
3.3.2    Multislice computed tomography 
Multislice computed tomography (MSCT) imaging was carried out on a Somatom 
Plus 4 Volume Zoom scanner (Siemens, Erlangen, Germany) with parameters of 120 
kV and 320 mAs. For image reconstruction, a high resolution kernel was applied 
(U90). Slices of 0.5 mm thickness and 0.5 mm spacing were acquired in a sequential 
scanning mode. 
 
3.3.3    Micro computed tomography 
For investigation using µCT, blood vessels were filled with a solidifying blood-pool 
contrast agent (Microfil; Flow Tech, Carver, MA, USA) forming a vascular cast. 
Under visual control, ready-made, non-diluted contrast agent was perfused manually 
using three different methods as described (Jorgensen et al., 1998; Kwon et al., 1998; 
Kantor et al., 2000). i) The pulmonary vascular tree was completely filled by 
intravenous in vivo injection via the jugular vein. ii) The pulmonary arteries were 
filled down to the capillary level by direct injection of contrast medium into the main 
pulmonary artery ex vivo. iii) The aorta and the arterial vessels were filled by 
injecting contrast media into a catheter inserted through the left ventricle. After 
perfusion and solidification of the contrast medium, the lungs were removed and 
scanned with a desktop µCT unit (Skyscan1072, Sky scan, Belgium) that has been 
previously described (Langheinrich AC. et al., 2004). In our setting, samples were 
positioned on a computer-controlled rotation stage and scanned over a half rotation 
(180°) with rotation steps of 0.675°, at 60 kVp, 100 µA. Raw data were reconstructed 
with a modified Feldkamp cone-beam reconstruction algorithm (Feldkamp et al., 
1989), resulting in 8-bit gray-scale images with (6 µm)3 isotropic voxels. Image 
processing and analysis were performed with the Analyze 6.0 software package 
(Analyze, Biomedical Imaging Resource, Mayo Foundation, Rochester, MN, USA). 
 
 
 
Materials and Methods                                                                                                25 
 
 
 
3.4    Histological methods 
3.4.1    Hematoxylin and Eosin (H&E) staining 
Three to five µm thick sections were prepared from paraffin embedded tissue 
samples. The sections were de-paraffinized by incubation in xylene solution 3 x 5 
min. Then the sections were fixed in acetone for 2 min on ice and incubated in 100%, 
90%, and 70% ethanol, and finally in dist. H2O, spending 3 min in each solution. 
Then the slides were incubated in fresh hematoxylin (Merck, Darmstadt, Germany) 
for 15 min and washed in dist. H2O for 20 min. Next, the slides were incubated with 
freshly prepared Eosin solution acidified with acetic acid (Sigma, Deisenhofen, 
Germany) for 1 min. The slides were then washed with dist. H2O for 5 min and 
dehydrated for 3 min per solution in 90% ethanol and 100% ethanol. Finally, the 
slides were air dried for 5 min and mounted with mounting medium. 
 
3.4.2    Assessment of microvessel density 
Detection of blood vessels was performed by immunohistochemistry for CD31. 
Frozen 5 µm tumor sections equilibrated to room temperature were fixed in acetone 
for 10 min. Endogenous peroxidases were blocked with 0.3% (v/v) hydrogen peroxide 
in methanol and then blocked with 5% (v/v) goat serum in PBS, followed by 
incubation with anti-mouse CD31 rat monoclonal antibody clone MEC13.3 (1:500, 
Pharmingen, San Diego, CA, USA). Sections were washed in PBS, and antibody 
binding was determined using a Vector ABC kit (Vector Laboratories, Burlingame, 
CA, USA). Negative control slides were obtained by omitting the primary antibody. 
After extensive washing, sections were stained with DAB and visualized under light 
microscopy. Areas of microvessel density were counted in a minimum of five 
microscopic fields with a 10X objective. Values were expressed as mean microvessels 
per field (Ravi et al., 2000). 
 
3.4.3    Apoptosis by cyto- and histochemistry 
Apoptosis in cultured cells and tumor sections was visualized using the terminal 
deoxynucleotidyl transferase (TdT) - mediated dUTP- biotin nick end labelling 
(TUNEL) method (alkaline phosphatase in situ cell detection kit, Roche, Mannheim, 
Germany). Frozen sections were fixed in 4% (v/v) paraformaldehyde for 1h,  
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permeabilized using Triton X-100 (Sigma, Deisenhofen, Germany), and then 
incubated at 37°C for 60 min with TUNEL reaction mixture. The staining was 
performed according to the manufacturer’s recommendations. The stained cells were 
viewed under the light microscope magnification 20X (Leica Instruments, Nussloch, 
Germany). Results, based on apoptosis, were indicated as the average number mean 
ratio of labelled nuclei to the total number of cells in five different fields (n=3). 
Positive control of TUNEL labeling was prepared using DNase I (Sigma, St. Louis, 
MO, USA) treatment. After pretreatment, histological sections were incubated with 
DNase I (5 µg/ml) in a 37°C humidified chamber for 10 min to induce DNA strand 
breaks. Negative control was obtained by omitting terminal transferase from the 
labeling procedure. 
 
3.4.4    Histology of fluorescent microsphere-infused lungs 
For cryosections, the fluorescent microsphere-infused (Number) lungs were inflated 
with Tissue-tek (Sakura Finetechnical Co. Ltd., Tokyo, Japan) in 0.9% NaCl (1:1). 
Cryosections with 15 µm slice thickness were made for histological examination 
using a Leica-CM 1900 Cryostat Microtome (Leica Instruments, Nussloch, Germany). 
Color and location of fluorescent microspheres within the lung and lung tumors were 
detected using a fluorescent microscope equipped with an IMT2RFL Reflected Light 
Fluorescence Attachment (Olympus Optical Co., Hamburg, Germany) multi-
wavelength fluorescent filter cube (Wagner et al., 2002). 
 
3.5    Molecular biological methods 
3.5.1    Construction of expression plasmid for HIF-1α 
For isolation of full length cDNA fragments of HIF-1α, we employed a nested RT-
PCR from RNA extracts of A549 cells. For maximal translation efficacy, we inserted 
the Kozak sequence (GCCGCCACCATGG) at the start codon of translation. The full 
length HIF-1α cDNA (Acc. No. NM_001530) was ligated into expression vector 
pMG (Invivogen, San Diego, CA, USA) and verified by sequencing (ABI Prism 310; 
PE Applied Biosystems, Foster City, CA, USA) (Hanze et al., 2003).  
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3.5.2    Real-time reverse transcription-polymerase chain reaction (RT-PCR) 
Cellular RNA was extracted from A549 tumors (n=3) using guanidine thiocyanate-
acid phenol (RNAzol B, WAK-Chemie, Germany). Approximately 2 µg of RNA per 
sample was copied to cDNA using reverse transcriptase (MMLV-RT) (Gibco-BRL, 
Karlsruhe, Germany) in a standard protocol with random hexamers. For the negative 
control, MMLV was omitted. Real-time PCR was performed using the ABI Prism 
7700 Detection system (Applied Biosystem, Weiterstadt, Germany) with SYBR-
Green as fluorescent dye, enabling real time detection of PCR products according to 
the manufacturer’s protocol (Hanze et al., 2003; Goyal et al., 2004). The following 
primer sets (+, sense; -, antisense), derived from the respective Genebank sequences, 
were employed: HIF-1α (Accession No. NM_001530) HIF-1α +: 5′- CCA TTA GAA 
AGC AGT TCC GC-3′, HIF-1α -: 5′-TGG GTA GGA GAT GGA GAT GC-3′, 
VEGF (Accession No. NM_003376) VEGF +: 5′-GGA GTG TGT GCC CAC CGA 
GGA GTC CAA C-3′, VEGF -: 5′-GGT TCC CGA AAC CCT GAG GGA GGC T-3′, 
and HPRT (Accession No. NM_000194 ) HPRT +: 5′-TCG AGA TGT GAT GAA 
GGA GAT GGG A-3′, HPRT -: 5′-TCA AAT CCA ACA AAG TCT GGC TTA T-3′. 
 
3.5.3    Gene expression array analysis 
Total RNA was isolated from blood obtained from immunized mice, which were 
injected previously with DC, LLC1 cells, hybrids, or PBS alone. Biotin-16-dUTP 
labeled cDNA probes were generated from 5 µg of RNA using a GE Array non-
radioactive Ampo Labeling-LPR Kit (Super Array Bioscience Corp., Frederick, MD, 
USA) and used to hybridize a GE Array Q series mouse common cytokine gene micro 
array (Super Array Bioscience, cat # MM-003) according to the manufacturer’s 
instructions. After hybridization, the membranes were developed according to the 
manufacturer’s instruction to yield luminescent signals, which were then captured on 
X-ray film (Hyperfilm ECL, (Amersham Pharmacia Biotech UK Ltd., 
Buckinghamshire, England) using Curix capacity plus film developer (AGFA 
Gevaert, Hamburg, Germany). The resulting image data were analyzed for differential 
gene expression patterns using GE Array Analyzer 1.2 (Super Array Bioscience 
Corp., Frederick, MD, USA) software. Loading was adjusted based on the intensity of 
hybridization signals relative to the housekeeping gene ß-actin. 
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3.5.4    Semiquantitative RT-PCR 
To validate the results obtained by microarray analysis, we evaluated the expression 
of six transcripts by semiquantitative RT-PCR. Although this is only a 
semiquantitative measure of transcript abundance, the strong expression differences of 
the selected genes among the groups legitimize this approach. Select genes included 
IL-2, IL-7, IL-13, IFNα-2, IFNα-4, and IFNα-11. Total RNA was isolated from mice 
blood using the ZR Whole Blood Total RNA Kit (Zymo Research Corp., Orange, CA, 
USA). First strand cDNA was synthesized by the ImProm-II™ Reverse Transcription 
System (Promega Corporation, Madison, WI, USA) using oligo (dT)12-18 primers 
according to the manufacturer’s instruction. Afterwards, 4 µl cDNA product, together 
with the appropriate primers, was used as a template in PCR amplifications. The final 
products were electrophoresed in 2% agarose gel and detected by ethidium bromide 
staining. The expression levels of ß-actin were monitored as a loading control. The 
following primer sets (+, sense; -, antisense) derived from the respective Genebank 
sequences were employed: IL-2 (Accession No. NM_001530) IL-2 +: 5′- TCC TCA 
CAG TGA CCT CAA GTC C - 3′, IL-2 -: 5′- TGA CAG AAG GCT ATC CAT CTC C 
- 3′, IL-7 (Accession No. NM_008371) IL-7 +: 5′ - ATC CTT GTT CTG CTG CCT 
GT - 3′, IL-7 -: 5′ - CCA GTG TTT GTG TGC CTT GT - 3′, IL-13 (Accession No. 
NM_008355) IL-13 +: 5′- AGA CCA GAC TCC CCT GTG CA - 3′, IL-13 -: 5′ - TGG 
GTC CTG TAG ATG GCA TTG - 3′, INFα−2  (Accession No. K01238) 
INFα−2 +: 5′ - TGA GCT ACT GGT CAA TCT GTT CTC - 3′, INFα−2 −: 5′ - TTT 
GTC TCA CAC TCA CTC CTT CTC - 3′, INFα−4 (Accession No. NM_010504) 
INFα−4 +: 5′ - GCC TGT GTG ATG CAG GAA - 3′, INFα−4 −: 5′ - TGC CAG 
CAA GTT GGT TGA G - 3′, INFα−11 (Accession No. M68944) INFα−11 +: 5′- 
AAG GTC CTG GCA CAA ATG Ag - 3′, INFα−11 −: 5′ - CAT TCC AAG CAG 
CAG ATG AAG - 3′, ß-actin Accession No. M12481) ß-actin +: 5′ - TGT TAC CAA 
CTG GGA CGA CA - 3′ and ß-actin −:5′ - AGG AAG GCT GGA AAA GAG C - 3′. 
 
3.6    Data analysis 
Proliferation and cytotoxic assays are given as mean ± SD. All other data are given as 
mean ± SEM. Differences between the groups were assessed by a student’s t test, with 
a p value < 0.05 considered significant.  
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4    Results 
 
4.1    Mouse models of Lung Cancer 
Two different cell lines (A549 and LLC1) were used in our studies to generate mouse 
models of lung cancer. A549 cells were derived from human lung adenocarcinoma, and 
LLC1 cells were derived from mouse lewis lung carcinoma (Fig. 2).  
A mouse xenograft tumor model was generated by subcutaneous injection of A549 
cells into immunodeficient mice (CD1 nude). Tumor growth was assessed for a period 
of five weeks. Tumor size increased with time and cell number dependent manner (Fig. 
3A). A syngeneic graft tumor model was generated by subcutaneous injection of LLC1 
cells into syngeneic C57/BL6 mice. Tumor growth was assessed for three weeks. 
Tumor size increased rapidly with time and cell number dependent manner (Fig. 3B). 
A lung tumor model was generated by intratracheal instillation of murine primary 
LLC1 cells into C57/BL6 mice. Tumor formation was confirmed by computed 
tomography systems and by light microscopy using Hematoxylin and Eosin (H&E) 
stainings.  
 
 
 
Figure 2: Cell morphology and mouse strains. (A) Adenocarcinoma (A549) and lewis lung carcinoma 
(LLC1) cell lines. Morphology was examined using phase contrast microscopy. The cells were counter 
stained with DAPI (Scale bar=100 µm). (B) CD1 nude and C57/BL6 mice strains were used for 
generating tumors. 
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Figure 3: Subcutaneous tumors, lung tumor detection, and measurement. (A) A549 cells were 
injected subcutaneously into CD-1 nude mice. Tumor size was measured over 5 weeks by digital calipers 
in a time-dependent manner (mean ± SEM). (B) LLC1 cells were injected subcutaneously into C57/BL6 
mice. Tumor size was measured over 3 weeks by digital calipers in a time-dependent manner (mean ± 
SEM). (C, D) LLC1 were cells instilled intratracheally into C57/BL6 mice. Derived lung tumors were 
detected with H&E staining and CT systems. Representative images from both control and tumor bearing 
mice are shown (O = Tumors). 
 
4.2    Role of HIF-1α on tumor growth of lung adenocarcinomas  
4.2.1    Characterization of cells transfected by HIF-1α 
To analyze the effect of HIF-1, the human adenocarcinoma cancer A549 cell line was 
transfected with a human HIF-1α cDNA expression plasmid. HIF-1α overexpressing 
cells were selected with hygromycin. These cells were characterized by 
immunostaining for HIF-1α, hypoxia-responsive reporter gene assay, and HIF-1 
dependent target gene VEGF expression (Fig. 4). The typical induction of HIF-
1α, which was further enhanced in case of HIF-1α overexpression, was demonstrated 
in hypoxic conditions. Also, VEGF concentration in culture supernatants was enhanced 
under hypoxic conditions and when HIF-1α was overexpressed.         
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Figure 4: Characterization of HIF-1 expression in stable-transfected A549 cells. (A) 
Immunocytochemistry for HIF-1α in normoxic and hypoxic A549 cells stable-transfected with empty 
expression plasmid (control) or with an expression plasmid carrying the HIF-1α cDNA (HIF-1α). (B) 
Hypoxia-responsive-element (HRE) reporter gene assay of samples described in A (mean ± SEM, n = 3, 
*p<0.05, paired t-test). (C) HIF-1α target-gene vascular endothelial growth factor (VEGF) concentration 
measured in supernatants from the samples described in A (mean ± SEM, n = 3, *p<0.05, paired t-test). 
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4.2.2    Effect of HIF-1α on proliferation and apoptosis in cultured cells 
To investigate the role of HIF-1α in cell survival and cell growth, the growth rates of 
HIF-1α overexpressing cells over a period of 8 days under normoxic and hypoxic 
conditions were measured (Fig. 5A). The growth rates decreased under hypoxic 
conditions in both control cells and HIF-1α transfected cells, reflecting a hypoxia 
induced growth arrest. However, HIF-1α transfected cells exhibited the lowest growth 
rates under both normoxic and hypoxic conditions. These data were confirmed 
measuring S-phase by thymidine incorporation (Fig. 5B). Control cells maintained 
under normoxic conditions exhibited the highest values, followed by control cells 
maintained under hypoxic conditions, while HIF-1α transfected cells again exhibited 
the lowest proliferations.  
 
 
 
 
 
 
 
Figure 5: Analysis of cell proliferation in stable-transfected A549 cells. (A). Growth curve of A549 
cells stable-transfected with empty expression plasmid (control) or an expression plasmid carrying the 
cDNA encoding HIF-1α (HIF-1α) measured by MTT assay under normoxic or hypoxic conditions (mean 
± SEM, n = 3, +p<0.05, comparison in normoxia; *p<0.05, comparison in hypoxia, paired t-test). (B) 
Thymidine incorporation after 24 h of hypoxic or normoxic exposure of cells stable-transfected with 
empty expression plasmid (control) or expression plasmid carrying HIF-1α (HIF-1α) (mean ± SEM, n = 
3, *p<0.05, paired t-test).  
 
We then analyzed cells grown in soft agar to address anchorage-independent growth as 
an in vitro measurement of tumorigenesis under long-term conditions. The HIF-1α 
transfected cells exhibited fewer colonies than did the control cells (Fig. 6A, B).  
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Figure 6: Soft agar cloning of stable-transfected A549 cells. A) A549 cells stable-transfected with 
empty expression plasmid (control) or expression plasmid carrying HIF-1α (HIF-1α) were cultured in 
soft agar to measure their potency of anchorage-independent growth. A representative figure from phase 
contrast microscopy is illustrated (Z indicates a typical colony). B) Quantification of colony forming 
units (mean ± SEM, n = 24, *p<0.05, paired t-test).  
 
The cultured cells were further analyzed cytochemically by TUNEL assay. We detected 
a greater increase in apoptosis under hypoxic versus normoxic conditions in both 
control cells and in HIF-1α overexpressing cells. Of the two groups, the HIF-1α 
overexpressing cells exhibited the greater increase in apoptosis, under both normoxic 
and hypoxic conditions (Fig. 7A, B).  
 
 
 
 
 
 
 
Fgure 7: Measurement of apoptosis in vitro. TUNEL assay in A549 cells stable-transfected with 
empty expression plasmid (control) or expression plasmid carrying HIF-1α (HIF-1α) cultured under 
normoxic or hypoxic conditions. (A) The TUNEL staining by cytochemistry in phase-contrast 
microscopy is illustrated (Z indicates non-apoptotic cells, X indicates apoptotic cells). (B) 
Quantification of apoptotic cells by counting microscopic fields (mean ± SEM, n = 15, *p<0.05, paired t-
test). 
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4.2.3    Effect of HIF-1α on tumor growth in vivo 
We further investigated the effect of HIF-1α overexpression on tumor growth in vivo. 
To this end, HIF-1α overexpressing cells were injected subcutaneously into nude mice. 
These mice developed tumors at the injection site. The size of tumor xenografts was 
measured over an eight-week period. The tumor xenografts derived from HIF-1α 
overexpressing cells were significantly smaller than those derived from control cells 
(Fig. 8A, B). To analyze the actual status of HIF-1α in these tumor xenografts, we 
analyzed RNA extracts of tumor tissues for HIF-1α mRNA and VEGF mRNA levels. 
We found increased levels of HIF-1α mRNA and VEGF mRNA; however, these levels 
were not significant for tumors derived from HIF-1α overexpressing cells (Fig. 8C, D). 
 
Figure 8: Tumor growth from cells stable-transfected with empty expression plasmid (control) or 
expression plasmid carrying HIF-1α ((HIF-1α)-transfected A549 cells). (A) Cells were injected 
subcutaneously into mice, and the tumor size was measured by digital calipers in a time-dependent 
manner (mean ± SEM, n = 12, *p<0.05, paired t-test). (B) Representative photograph of mice illustrating 
the development of subcutaneous tumors eight weeks after injection of cells into the hind flank. (C, D) 
Real-time RT-PCR analysis of HIF-1α mRNA and vascular endothelial growth factor (VEGF) mRNA 
(bottom) from RNA extracts of tumors derived from HIF-1α overexpressing or control cells. Data are 
normalized to the mRNA level of the housekeeping gene hypoxyphosphoribosyl transferase (HPRT). To 
demonstrate the integrity of the PCR products, an agarose gel of PCR fragments, stained with ethidium 
bromide, is included. The signals are only visible after reverse transcription (+RT), demonstrating that 
the signal is really derived from mRNA, while samples without reverse transcription (-RT), performed as 
a negative control, showed no signal. 
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4.2.4    Effect of HIF-1α on tumor vascularity and apoptosis 
Hypoxia is a HIF-1 dependent stimulus for triggering angiogenesis, a process largely 
mediated by VEGF. We therefore analyzed vascularization of tumor xenografts derived 
from HIF-1α overexpressing or control cells by vessel staining the endothelial cell 
marker CD31 (Fig. 9A, B). Quantitative analysis performed by counting vessels in 
different tumor areas indicated a higher vascular density in tumors derived from HIF-1α 
overexpressing cells. Finally, tumor sections were also analyzed for apoptosis by 
TUNEL assay (Fig. 9C). The HIF-1α overexpressing tumors exhibited enhanced 
apoptotic rates in different sections investigated when compared to control tumors. 
Necrosis was observed in the central areas of both HIF-1α overexpressing and control 
tumors sections.  
 
Figure 9: Quantification of vascular density and apoptosis: (A) Quantification of vascular density in 
various tumor sections (right part, R; left part, L; lower part, D) of HIF-1α overexpressing (HIF-1α) and 
control tumors (control). Shown is the immunohistochemistry of CD31 staining of frozen tumor sections. 
(B) The bar graph below shows quantification after counting representative fields from the microscopic 
images (mean, SEM, n =36, *<0.05, paired t-test). (C) Apoptosis in various tumor sections (right part, R; 
left part, L; lower part, D; central part, C) of HIF-1α overexpressing (HIF-1α) and control tumors 
(control) after eight weeks of cell injection. Tumors derived from HIF-1α overexpressing cells showed 
stronger apoptotic staining than control tumors (Z labels apoptotic cell). 
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4.3    Anti-tumor effects of LLC1/DC fusion hybrids 
4.3.1    Characterization of LLC1/DC cell hybrids 
Activated DCs are potent inducers of T-lymphocyte-mediated immunity. To overcome 
the poor immune response particularly against weakly immunogenic tumor cells, we 
fused DC with LLC1 cells from C57/BL6 mice. Surface phenotypes of DCs and fused 
cells were analyzed by flow cytometry. LLC1 cells were stained with the green 
membrane marker PKH-67 (Fig. 10A). The characteristic phenotype and activation of 
bone marrow derived DCs was confirmed by expression of CD11c (Fig. 10B), B7.1 
(Fig. 10C) and MHC class II (Fig. 10D) in about 60% of analyzed cells. Further, 
staining of both LLC1 marker and CD11c showed a few double positive cells in 
DC/LLC1 mixtures (Fig. 10E) in contrast to DC/LLC1 hybrids that showed about 50% 
of double positive cells (Fig. 10F).  The fusion efficiency of DC/LLC1 hybrids was also 
confirmed by double staining with co-stimulatory molecules, B7.1 and MHC class II 
(Fig. 10G, H).  
 
 
 
 
 
 
 
 
 
Figure 10: Fusion rate: (A) PKH-67 fluorescence on LLC1 cells. (B) Expression of CD11c, (C) 
expression of B 7.1, and (D) expression of MHC class II on dendritic cells. (E) CD11c and PKH-67 
fluorescence on mixture of DC/LLC1. (F) Double staining of PKH-67 with CD11c or (G) B 7.1 or (H) 
MHC class II on fused Hybrids. Surface fluorescence intensity was evaluated by flow cytometry. 
 
To evaluate the success of cell fusions, fluorescence microscopy was used to determine 
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LLC1 and DCs, showed green or red staining of the cell membrane, respectively (Fig. 
11A-D). HCs appeared yellow because of the double positivity for both membrane 
markers, PKH-67 and PKH-26 (Fig. 11E, F). As shown in Figure 11E, F, we also 
observed several green cells, indicating unfused LLC1 cells, and a few DCs and LLC1 
cells with membrane overlapping. Moreover, on the second day following the fusion 
procedure, HCs showed a higher percentage of double positive cells and a strong 
yellow staining when compared to 1 day old HCs. Based on this observation, we 
assumed that fusion efficiency and proliferation of HCs increased with time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Fluorescence micrographs of LLC1, dendritic cells, and fusion hybrids. (A) PKH-67 
labeled LLC1 cells, including (B) nuclei stain DAPI blue. (C) PKH- 26 labeled DCs, including (D) nuclei  
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stain DAPI blue. (E) Double stained HCs, including (F) nuclei stain DAPI blue. ► indicates HCs; → 
indicates unfused LLC1 cells. Scale bar: 100 µm.  
 
4.3.2   Proliferation and cytotoxic response of hybrid immunized mice T-
lymphocytes 
Syngeneic naive mice were footpad immunized with irradiated LLC1, DCs, DC/LLC1, 
DC/LLC1 lysate, Hybrids or PBS alone as described in Material and Methods. After 
immunization, spleen (SC) and lymph node cells (LNC) from each group of mice were 
harvested and stimulated in vitro with syngeneic LLC1, DCs, DC/LLC1, DC/LLC1 
lysate, HCs or allogeneic SC/LNCs (BALB/c derived) for 4 days. Only lymphocytes 
obtained from mice immunized with HCs showed a slight response to syngeneic naive 
tumor cells. T-cell response against tumor/DCs cell mixture or HCs was detected in all 
effector cell populations with the strongest response of lymphocytes obtained from 
mice immunized with HCs (Fig 12A).  
To assess the induction of LLC1 specific cytotoxicity by HCs, spleen cells from each 
group of immunized mice were harvested and tested against LLC1 tumor cells, 
B16/F10 (2nd party tumor) cells or allogeneic lymphocytes. The results showed a 
negligible cytotoxic response of T-lymphocytes from mice immunized with DCs 
against LLC1 or B16/F10 tumor cells. In contrast, T-lymphocytes from mice 
immunized with HCs specifically targeted LLC1 tumor cells, but not B16/F10, a 
second party tumor cells (Fig. 12B). 
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Figure 12: Proliferative activity and cytotoxicity of T-lymphocytes from immunized mice. (A) 
Proliferative activity of spleen cells (SC) and lymph node cells (LNC) collected from mice immunized 
with irradiated LLC1, DC, DC/LLC1, DC/LLC1 lysate, HC or PBS as control in response to different 
irradiated stimulator cells. SC/LNCs were either cultured with tumor cells LLC1, DC, DC/LLC1, 
DC/LLC1 lysate, HC or with allogeneic lymphocytes (BALB/c). Proliferative activity was determined by 
[3H] thymidine incorporation after 3 days of culture. Mean values + SD of the proliferation index (cpm 
of test well/cpm of control) of triplicate cultures are shown. 
(B) Cytotoxic capacity of CTL spleen (SC) and lymph node cells (LNC) collected from mice immunized 
as described above were tested against LLC1 cells, syngeneic 2nd party tumor cells (B16F10) and 
allogeneic (BALB/c) lymphocytes at an effector:target ratio of 40:1. Mean percentages lysis values for 
four different experiments are shown. 
 
4.3.3    Cytokine profile of hybrid immunized mice  
To analyze LLC1/DC hybrid regulated cytokine genes, cellular RNA from LLC1, DCs, 
DC/LLC1, DC/LLC1 lysate, Hybrids or PBS immunized mice blood was isolated, 
reversed transcribed and hybridized with mouse common cytokine gene array. As 
shown in figure 13A, the expression of Interferon alpha family, gene B, 1, 2, 4, 5, 6, 7, 
8, and 11, Interleukin 2, 7, 13 and also mouse stem cell factor (SCF), mast cell growth 
factor (MGF) kit ligand, and Tumor necrosis factor super-family member 13b were 
predominantly expressed in HCs immunized compared to all other control (LLC1, DCs 
and PBS) mice. These scores were normalized using the scores of ß-actin spotted on the 
same membrane. 
To further verify the mouse cytokine gene array results, we performed semi-
quantitative RT-PCR from HCs and control immunized mice. As shown in figure 13B  
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Interferon alpha family 2, 4, 7 and 11, Interleukin 2, 7, 13 were upregulated compared 
to all other control groups, confirming the micro array results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Representation of mouse common cytokine gene arrays from immunized mouse blood. 
(A) Mouse common cytokine gene arrays incubated with cDNA probes generated from immunized LLC1,  
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DC, DC/LLC1, DC/LLC1 lysate, HC or PBS alone. The detection of multiple cytokines by various 
samples was listed below. 
1=ß actin, 2=Tumor necrosis factor super family member 13b, 3=Interleukin 2, 7, 13 and also mouse stem 
cell factor (SCF), mast cell growth factor (MGF) kit ligand, 4= Interferon alpha  
family, gene B, 1, 2, 4, 5, 6, 7, 8, and 11, 5 = Transforming growth factor, beta 1 (Tgf b1), 6 = 
Lymphotoxin B (Ltb), 7 = Interleukin 16 (IL 16), 8 = Protein phosphate 1, catalytic subunit, alpha isoform 
(Ppp1ca).  
(B) The mRNA level of each cytokine (IL-2, IL-7, IL-13, IFNα-2, IFNα-4 and IFNα-11) that exhibited 
significant regulation by HCs using cytokine gene arrays was analyzed by semi-quantitative reverse-
transcriptase-PCR as described in "material and methods." The abundance of each cytokine mRNA is 
indicated relative to the ß-actin in immunized LLC1, DC, DC/LLC1, DC/LLC1 lysate, HC or PBS alone. 
 
4.3.4   Immunization with hybrids induce growth retardation of LLC1 tumor 
challenge 
To determine whether hybrid immunization affects tumor growth, groups of syngeneic 
naive mice were immunized twice and then challenged with tumor cells and monitored 
for tumor growth. 
The results showed that mice immunized with LLC1 or PBS were all positive for tumor 
growth in the 1st week and 60% died within 28 days after challenge with LLC1 tumor 
(Fig.14A). Mice immunized with DCs or DC/LLC1 or DC/LLC1 lysate showed a slight 
decrease in tumor growth. However, mice immunized with HCs demonstrated a 
significant reduction (23%) in tumor growth and a delay in tumor development. These 
in vivo data were underlined by the in vitro evaluation of proliferation and cytotoxicity 
(Fig 14B, C). SC and LNC harvested from immunized and challenged animals 28 days 
after tumor challenge, showed a slight T-cell response after incubation with stimulator 
cells compared with results from animals that only received immunization. However, 
tumor challenge was not sufficient to trigger T-cell proliferation from animals 
immunized with LLC1, DCs, DC/LLC1 and DC/LLC1 lysate against naive tumor cells. 
In contrary, cytotoxicity assays with a specific lysis of 40% against naive LLC1 tumor 
cells induced by lymphocytes obtained from animals immunized with HCs. Otherwise, 
only T cells from DC, DC/LLC1 and DC/LLC1 lysate-immunized animals developed 
approximately 16% lysis activity as compared to 5% by unchallenged effector cells. 
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Figure 14: Anti-tumor effects of hybrid immunization. (A) Mice were immunized twice with PBS 
(), irradiated LLC1 (O), DC (▼), DC/LLC1 ( ), DC/LLC1 lysate (■) or HC (□) and were challenged 
with LLC1 cells s.c after the 2nd immunization. Tumor volume measured chronologically after tumor 
challenge. Data are presented as the average tumor volume ± SEM of 10 mice.  *, p<0.05 versus PBS and 
LLC1; †, p<0.05 versus DC 
(B) Proliferative activity of SC/LNCs in response to different irradiated stimulator cells. SC/LNCs were 
collected from mice immunized with irradiated LLC1, DC, DC/LLC1, DC/LLC1 lysate, HC or PBS as 
control. SC/LNC was either cultured with tumor cells LLC1, DC, DC/LLC1, DC/LLC1 lysate, HC or 
with allogeneic lymphocytes (BALB/c). Proliferative activity was determined by thymidine incorporation 
after 3 days of culture. Mean values + SD of the proliferation index (cpm of test well/cpm of control) of 
triplicate cultures are shown. 
(C) Cytotoxic capacity of SC/LNCs were tested against LLC1 cells, syngeneic 2nd party tumor cells and 
allogeneic lymphocytes at an effector:target ratio of 40:1. SC/LNC were collected as described above. 
Mean percentages lysis values from 4 different experiments. 
 
4.3.5    Anti-tumor effect of hybrid vaccination  
To examine the anti-tumor effects of HC vaccination on LLC1 subcutaneous tumors, 
LLC1 tumor inoculated mice were vaccinated with DC, DC/LLC1, DC/LLC1 lysate, 
Hybrids or PBS alone. As shown in Fig 15A, mice vaccinated with DCs as well as with 
mixture of DC/LLC1 or DC/LLC1 lysate, had no greater protection against LLC1  
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tumor challenge than the naive group (PBS alone), whereas in animals vaccinated with 
HCs, 60% growth reduction was achieved. Furthermore, the therapeutic effects of HC 
vaccination against LLC1 challenge was persistent and effective for longer periods (28 
days). To determine whether vaccination can elicit T-lymphocyte proliferation and 
tumor specific cytotoxicity, T-lymphocytes from the vaccinated mice were exposed to 
stimulator cells or target tumor cells, respectively. As anticipated T-lymphocytes 
derived from HC vaccination showed increased proliferation indices against all 
stimulator cells and a 65% tumor specific cytolytic activity (Fig 15B, C) compared to 
T-lymphocytes derived from DC, DC/LLC1 and DC/LLC1 lysate vaccination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Lower tumor development by hybrid vaccination. (A) 7 days after tumor challenge of 
LLC1 cells, mice were vaccinated twice with PBS (), irradiated LLC1 (O), DC (▼), DC/LLC1 ( ), 
DC/LLC1 lysate (■) or Hybrids (□). Tumor growth in each group of mice was recorded with 4-day 
interval of vaccination. Data are presented as the average tumor volume ± SEM of 10 mice. *, p<0.05 
versus PBS and LLC1; †, p<0.05 versus DC; ‡, p<0.05 versus DC/LLC1 mixture, ‡†, p<0.05 versus 
DC/LLC1 lysate 
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(B) Proliferative activity of lymphocytes (SC/LNC) in response to different irradiated stimulator cells. 
SC/LNCs were collected from tumor bearing mice vaccinated twice with irradiated LLC1, DC, 
DC/LLC1, DC/LLC1 lysate, HC or PBS as control. SC/LNCs were either cultured with tumor cells 
LLC1, DC, DC/LLC1, DC/LLC1 lysate, HC or with allogeneic (BALB/c) lymphocytes. Proliferative 
activity was determined by [3H] thymidine incorporation after 3 days of culture. Mean values + SD of 
the proliferation index (cpm of test well/cpm of control) of triplicate cultures are shown. 
(C) Cytotoxic capacity of lymphocytes (SC/LNC) were tested against LLC1 cells, syngeneic 2nd party 
tumor cells (B16F10) and allogeneic (BALB/c) lymphocytes at an effector:target ratio of 40:1. SC/LNC 
were collected as described above. Mean percentages lysis values for four different experiments are 
shown. 
 
4.3.6    Adoptive therapy of established syngeneic tumors with hybrids primed T-
cells 
To assess the therapeutic potential of hybrid primed T-cells in established LLC1 
tumors, we isolated SC/LNCs from DC, DC/LLC1, DC/LLC1 lysate, HC or PBS 
immunized C57BL/6 mice. These cells were adoptively transferred twice, with a 4 days 
interval, to LLC1 tumors bearing mice. In all the three treatment groups, visible tumor 
growth had started 4 days after tumor inoculation (Fig 16A). However, a dramatic 
reduction of tumor growth was observed 12 days after tumor implantation in mice 
treated with HC primed T cells (48%) compared with mice vaccinated with DCs (14%), 
DC/LLC1 (18%) or DC/LLC1 lysate (21%). Sustained growth retardation was observed 
at day 12 to day 28 with a mean reduction of 51.1%. In addition, we observed an 
increase in spleen size of mice treated with primed T-cells derived from mice 
vaccinated with HCs, thereby indicating an increased population of T-cells mediating 
tumor suppression (Fig 16B). These in vivo data were further supported by proliferation 
and cytotoxic assays. As shown in Fig 16C, D, T -lymphocytes harvested from the 
adoptively treated SC/LNCs HCs demonstrated an improved proliferation capacity 
against all stimulator cells, with a marked enhancement against hybrid stimulators. In 
line with these findings, LLC1 tumor specific CTL activity induced by the T -
lymphocytes harvested from the adoptive treated SC/LNCs HCs was significantly 
elevated (50%) compared to all other groups including unchallenged effector cells. 
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Figure 16: Suppression of LLC1 tumor growth in mice given adoptive immunotherapy (A) LLC1 
tumors bearing mice were treated with SC/LNC cells isolated from PBS (), irradiated LLC1 (O), DC 
(▼), DC/LLC1 ( ), DC/LLC1 lysate (■) or HC (□) immunized mice. Tumor development was monitored 
and recorded chronologically after tumor challenge. Data are presented as the average tumor volume ± 
SEM of 10 mice. *, p<0.05 versus PBS and LLC1; †, p<0.05 versus DC; ‡, p<0.05 versus DC/LLC1 
mixture, ‡†, p<0.05 versus DC/LLC1 lysate 
(B) Representative spleens, dissected 28 days after tumor challenge.  
(C) Proliferative activity of SC/LNCs in response to different irradiated stimulator cells. SC/LNCs were 
collected from tumor bearing mice challenged with SC/LNC obtained from immunized mice. SC/LNCs 
were either cultured with tumor cells LLC1, DC, DC/LLC1, DC/LLC1lysate, HC or with allogeneic 
(BALB/c) lymphocytes. Proliferative activity was determined by thymidine incorporation after 3 days of 
culture. Mean values + SD of the proliferation index (cpm of test well/cpm of control) of triplicate 
cultures are shown. 
(D) Cytotoxic capacity of SC/LNCs were tested against LLC1 cells, syngeneic 2nd party tumor cells and 
allogeneic lymphocytes at an effector:target ratio of 40:1. SC/LNC were collected as described above. 
Mean percentages lysis values from 4 different experiments. 
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4.4    Detection of pulmonary nodules in a lewis lung carcinoma model by fpvCT 
and MSCT 
Scanning with both modalities (MSCT and fpvCT) could be performed without major 
motion artifacts; therefore, overall image quality was adequate for assessment of either 
scan. Comparing axial slices from both computed tomography systems; higher spatial 
and therefore anatomical resolution was obvious in fpvCT. Bronchial structures were 
clearly delineated and distinguished from pulmonary arteries, pulmonary veins, and 
lung parenchyma in this modality. The bronchial system and the whole lung could be 
tracked from its outlet for three-dimensional segmentation (Fig. 17). The four segments 
of the right lung could vaguely be distinguished in fpvCT, especially in the case of 
pleural effusions, while there was no differentiation possible with MSCT.  
 
                     
 
Figure 17: 3D segmentation of the lung. In panel (A), a 3D segmentation of the entire lung is shown. 
The trachea (t), left and right bronchus (lb, rb), and the division of the latter in its segmental bronchi are  
demonstrated. The left lung (ll) consists of only one segment, while the right lung (rl) has four segments 
where the cardiac lobe (cl) hands over to the right side. With the 3D software, virtual bronchoscopy can 
be performed. In panel (B), a view on the diversion of the trachea (cross) into the right bronchus (rb) and  
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left bronchus (lb) is indicated. Single reformatted slices (coronal view) can be combined to a 3D dataset, 
where, in this Maximum Intensity Projection (C, D), the tumor masses (arrows in C and D) are shown as 
enlargements of the mediastinum, known in its human correlate from chest imaging.  
 
Pulmonary nodules were better delineated by fpvCT than by the clinical scanner. 
Detection of small nodules, which were frequently attached to pulmonary arteries, was 
improved in coronary reformatted images. Isotropic voxels were provided, and high 
resolution was obtained for both axial images and any reformatted slice (Fig. 18A, B). 
Therefore, better delineation and detection of tumors was possible in coronal planes, as 
the nodules could be distinguished from the pulmonary arteries, which were visualized 
in their course from their origin in the pulmonary artery to the periphery. The tumors 
showed preferential growth along the pulmonary arteries that was also better observed 
in coronal slices in fpvCT.  
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Figure 18: Display of coronal and axial reformatted images of datasets acquired with fpvCT and 
MSCT. (A) The first tumor nodules were detected with fpvCT on day 9 (white arrows); these nodules 
were not displayed in MSCT. Tumor induction was proven on day 11 in MSCT; however, the small 
nodules did not appear in later stages as in fpvCT (open arrow). The tumors were much better delineated 
in fpvCT images. The coronal reformatted images from MSCT appeared blurred due to anisotropy (less 
resolution in z-direction than in-plane). Isotropic voxels in fpvCT enabled more accurate volumetry of 
the nodules. (B) Axial slices acquired with fpvCT (upper row) and MSCT (lower row). The fpvCT 
images were of a higher quality and had less noise. Though the animal was freely breathing, the spine 
and ribs were much better delineated in fpvCT than in MSCT. The small nodule detected in fpvCT on 
day 9 was not visible in the corresponding image from MSCT (arrows). Due to the better resolution, the 
tumor border is more clearly delineated in fpvCT. 
 
 
In Table 2, the time-point of lung nodule detection is stated in MSCT versus fpvCT, 
and the results on the last scan are opposed to investigation in histology. Tumor 
inoculation was successful in four mice (Mouse2 to Mouse5 in Table 2), visualized in 
longitudinal imaging, and proven in histology. Both imaging modalities revealed a 
good overall specificity of 100%. Comparing the scans on day 11 with the subsequently 
performed histology, MSCT scans created a sensitivity of 68% compared to 80% in 
fpvCT. Images taken before euthanasia of the animals could not be compared with ex-
vivo investigation; therefore, a gold standard was not available. The only comparison 
possible was made by evaluating MSCT versus fpvCT, taking the later development of 
tumor evolution into account. A good validation was given with fpvCT, as all tumors 
detected in fpvCT could be followed in their growth and were evidenced in the final 
investigation with histology. Therefore, we could legitimately assume that positive 
evaluation of a nodule in fpvCT mirrored tumor growth. Relying on these assumptions, 
we found an overall sensitivity of 50% in MSCT compared to fpvCT.  
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   day 3 day 5 day 7 day 9 day 11 histology    
left          Mouse 1 
right          
left   + + + • Key: detected with Mouse 2 
right + + + + ⊕ •  + fpvCT 
left        ⊕ fpvCT and MSCTMouse 3 
right   + ⊕ ⊕ •  • histology 
left  + ⊕ ⊕ ⊕ •    Mouse 4 
right    +      
left    + + •    Mouse 5 
right      •    
 
 
Table 2: Lung tumor analysis. The results for the left and right lung of the five mice are tabulated for 
each day of investigation with fpvCT and MSCT, and finally for histology on the 11th day after tumor 
implantation. “+” means nodules were detected with fpCT but not MSCT, “⊕” indicates nodule detection 
with both fpvCT and MSCT, and presence of nodules found with histology is shown by “•”. Except in 
mouse 4, all tumors were detected earlier in fpvCT. Sensitivity was superior in fpvCT compared to 
MSCT in the end-point of the investigation, while the specificity was 100% for both systems. 
 
In addition to evidence of successful tumor inoculation, side effects from tumor growth, 
like pleural effusions and complications of intubation and tumor instillation, were 
detectable. Pulmonary infiltrates in the early course of the disease and pneumo-
mediastinum and pneumothorax were observed.  
Correlating the histological slices with images from fpvCT concerning the tumor 
diameter, we found a sensitivity of the system with 0.2 mm (Fig. 19A). However, 
shrinking artifacts may have appeared during histological preparation. Furthermore, 
volumetric measurements could easily be acquired with the three-dimensional datasets 
from fpvCT if there were good delineation from arteries and veins (Fig. 19B). 
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Figure 19: Comparison between fpvCT image and histology is displayed. (A) The small tumor 
adjacent to the bronchus (arrow) was measured with 200 µm in histology and vaguely seen in fpvCT. 
Therefore, 200 µm seems to be the cut-off resolution for lung nodules in fpvCT. Larger nodules could 
easily be identified in fpvCT (open arrow, arrow head). (B) In this panel, a three-dimensional 
reconstruction of a lung nodule is shown in fpvCT in the axial (A), sagittal (B), and coronal (C) planes.  
There is no obvious loss of resolution in the reformatted planes (B, C) as compared to the in-plane (axial, 
A) scanning slice. This nodule was measured with 0.7 mm³. A semi-automated threshold based algorithm 
was used for segmentation in the post-processing software. 
 
4.5   Quantitative analysis of lung tumor vessel content by micro computed 
tomography  
Both intrapulmonary and intravenous blood-pool CM injection kept the lungs fully 
inflated after extirpation and thereby enabled the detection of multiple lung tumors with 
µCT. These results closely corroborated the histological investigations (Fig. 20A, B). 
Quantitative volumetric measurements of extracted tumors and vascular fractions were 
made possible by this radiological modality (Fig. 21A, B). 
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Figure 20: Comparison of µCT and microscopic images. (A) Transverse µCT image. (B) 
Conventional microscopic image of corresponding µCT section (magnification, 5X). Samples were 
scanned with µCT. The reconstructed images had isotropic voxels with 8 µm side-length. This section 
was subsequently stained with H&E for microscopic examination. Note tumor mass with contrast filled 
microvasculature (1), pulmonary artery (2), bronchus (3) and inflated lung (4).  
 
 
 
Figure 21: Quantitative volumetric measurements of extracted tumors and vascular fractions. (A) 
Single slice of the extracted tumors (A, B). Segmentation of the vascular fraction at the defined threshold 
(C) and in the entire extracted tumor by Volume Rendering Technique (D). (B) Volumetric histogram of 
the entire extracted tumor (A), the tumor without vessels (B), and the vessels of the tumor (C).Vascular 
fraction of the extracted tumor. Total tumor volume 0.7355 mm3; ■ tumor volume without vessels 
(mm3); □ vascular volume of the tumor (mm3) (D). 
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4.6   Distribution of pulmonary and bronchial blood supply to lewis lung 
carcinomas  
4.6.1    Tumor model 
In H&E-stained histological images at 1, 3, 5, and 7 days following tumor instillation, 
tumors were noted at the peripheral parenchymal region away from the airways. The 
tumors increased in size from day 3 to day 7 (Fig. 22A), growing from 0.73±0.10 mm 
to 1.62±0.08 mm in diameter (Table 1). Additionally, in vivo images obtained with 
fpvCT before and after instillation of LLC1 cells in the same mice (Fig. 22B) detected 
rapid tumor development, with diameters increasing from 1.09±0.14 mm at day 3 to 
1.93±0.10 mm at day 7, measured in reformatted images (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Analysis of lung tumor growth by histology and fpvCT. (A) Histological analysis with 
H&E staining of mice lung tumor tissue sections after intratracheal instillation of saline or LLC1 cells. 
The microphotographs demonstrate a time-dependent increase in tumor size, with an invasive growth 
(n=6 at each time point, bar = 300 µm); Black arrow indicates tumor. (B) Tumor detection with fpvCT 
in C57/BL6 mice in a longitudinal study, with scanning at days 3, 5, and 7 after LLC1-tumor instillation. 
Representative sagittal images from independent experiments (n=12). Yellow arrow indicates tumor 
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Table 3: Measurement of tumor growth by histology and fpvCT. Measurement of tumor diameter 
obtained from H&E staining and fpvCT. H&E values represent the average diameter of typical tumors 
(n=6, at each time points). FpvCT values represent the average diameter over time of a specific tumor 
selected in each of 12 mice.  
 
4.6.2    Fluorescent microspheres in LLC1 tumor lungs 
Microscopic images of normal lungs revealed yellow microspheres originating from the 
pulmonary artery and spread throughout the parenchyma (Fig. 23C), as well as red 
microspheres, originating from the bronchial artery, close to the terminal bronchi and 
parenchyma (Fig. 23E, G). The parenchymal presence of microspheres from the 
bronchial artery might be explained by arterial anastomoses between the bronchial and 
pulmonary circulation and precapillary bronchial pulmonary connections of C57/BL6 
mouse lung. 
Furthermore, microscopic images of both normal and tumor lung cryosections revealed 
a predominance of yellow microspheres in both lung tissue and tumor tissue (Fig. 23C, 
D). In contrast, red microspheres were almost exclusively found in the lung tissue, with 
a predominant location adjacent to the bronchi (Fig. 23E, F). The absence of red 
microspheres in tumors indicated little or no perfusion of the tumor via systemic 
circulation. This observation was further confirmed in lung sections from mice that had 
microspheres introduced into both systems simultaneously (Fig. 23G, H). 
 
 
 
Control                             no tumor                    no tumor
3 days                              0.73 ± 0.10 mm                     1.09 ± 0.14 mm
5 days                              1.13 ± 0.12 mm                     1.47 ± 0.17 mm
7 days                              1.62 ± 0.08 mm                     1.93 ± 0.10 mm
Tumor H&E staining 
(Diameter)
fpvCT
(Diameter)    
Tumor growth
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Figure 23: Blood vessel supply of healthy and tumor-bearing lung tissue analyzed by fluorescent 
microspheres. Cryosections of mouse lungs with (B, D, F, H) or without (A, C, E, G) tumors were 
analyzed with fluorescent microscopy for the presence of injected fluorescent microspheres. Lungs were 
fixed 7 days after LLC1 instillation when successful tumor induction was confirmed by fpvCT. The 
tumor lung sections show the presence of the solid tumor within the lung. Yellow fluorescent 
microspheres in control lung (C) and tumor lung (D), injected into the pulmonary artery, show the 
localization of yellow microspheres in both lung and tumor (D). Red fluorescent microspheres in control 
lung (E) and tumor lung (H), introduced via the bronchial artery, resulted in detection around the 
bronchial branch (E) or parenchyma (F). This observation was confirmed with simultaneous injection of 
both yellow and red fluorescent microspheres in control lung (G) and tumor lung (H) (n = 12). 
Arrowhead indicates yellow microspheres; chevron indicates red microspheres; arrow indicates tumor.  
 
The microspheres lodged in lung and tumor preparations were counted under 
fluorescent microscopy (Table 4). The number of yellow microspheres (supplied by the 
pulmonary system) was 9117 (±113) per mg. of lung weight and 247 (±10) per mg of 
tumor weight, indicating that the tumor was less perfused than the healthy lung  
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parenchym (Table 4). The number of red microspheres (supplied by the bronchial 
system) was 713 (±58) per mg of lung weight and 4.5 (±1.9) per mg of tumor weight 
(Table 4). Furthermore, analysis of the relative vascular supply revealed an average 
ratio of pulmonary to systemic microspheres of 52:1 (± 0.0084) (tumor) and 13:1 (± 
0.0069) (lung), a 4-fold greater ratio, confirming that the pulmonary arteries were the 
major feeding vessels to the tumor vasculature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Analysis of pulmonary and systemic blood flow markers. Recovery of red and yellow 
fluorescent microspheres in the lung and lung tumors after injection of 1.5 x 105 red (left ventricle) or 
yellow (right ventricle) colored fluorescent microspheres (mean, SEM, n=12). 
 
4.6.3    Analysis of micro computed tomography images 
To identify the source of tumor vascularization, the lung vasculature was filled in three 
ways as described in materials and methods. Intravenous injection of contrast medium 
via the jugular vein resulted in complete fixation of the pulmonary vascular tree with 
preservation of both microarchitecture and three-dimensional interconnectivity. In  
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comparison, ex vivo administration of contrast medium via the pulmonary artery 
resulted in successful filling of the pulmonary arteries down to the capillary levels.  
Both filling methods provided a clear visualization of the pulmonary artery branching 
to LLC1 lung tumors. The third filling approach, administration of contrast medium via 
the aorta, demonstrated both the origin of the bronchial artery at the level of main stem 
bronchi branching from the subclavian artery and the negligible role of bronchial 
arteries to LLC1 lung tumors. 
For two or three dimensional presentations of intrapulmonary tumors and their 
vascularization, µCT images were reconstructed using 3D maximum intensity 
projection (MIP), 3D volume-rendering technique (VRT), and 2D multiplanar 
reconstruction (MPR). The 3D VRT µCT images (Fig. 24A, B) of contrast medium-
filled lungs clearly showed branching and distribution of the pulmonary artery 
throughout the whole lung (Fig. 24A). The origin of the bronchial artery at the level of 
main stem bronchi branching from the subclavian artery was also visualized (Fig. 24B).  
 
 
 
Figure 24: Volume rendering technique (VRT) images of the µCT. 3D VRT image of the contrast-
fluid-filled pulmonary artery showed branching and distribution of the pulmonary artery (PA) throughout 
the whole lung. (A) 3D VRT image of the contrast-fluid-filled aorta showed systemic arteries (B) The 
main anatomical features, such as the origin, branches, and topography of the aorta (AO), including the 
left bronchial artery (LBA) branching from the left subclavian artery (LSA). In addition, the presence of 
right subclavian artery (RSA), internal thoracic artery (ITA), and coronary artery (CA) were also 
demonstrated (n=12).  
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3D MIP µCT image of contrast medium-filled lungs displayed fewer pulmonary vessels 
draining into tumors (Fig. 25A). In addition, coronal 2D MPR serial images of the 
tumor lungs showed the entry and branching of the pulmonary artery in the LLC1 
tumor mass (Fig. 25B). This was demonstrated more clearly on the magnification MIP 
image view (Fig. 25C). All vascular filling approaches displayed branching of small 
pulmonary vessels inside the tumors without bronchial arterial branching.  
These observations obtained from µCT scanning, along with the results obtained with 
fluorescent microspheres, confirmed that the pulmonary artery was the predominant 
tumor blood supplier.  
 
 
 
Figure 25: Maximum intensity projection (MIP) and multiplanar reconstructions (MPR) images of 
the µCT. 3D MIP image of the contrast-fluid-filled pulmonary artery shows branching and distribution 
of the pulmonary artery (PA) through the tumor mass (TM). In addition, the main anatomical features, 
such as trachea (TR), mediastinum (M), and esophagus (ES), are also visible (A). Coronal 2D MPR 
images of the tumor lung shows the pulmonary artery (PA) passing through the LLC1 lung tumor mass  
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(TM) (B). Magnification of 3D MIP image shows the increase of pulmonary artery (PA) vessel density 
around the tumor mass (TM) and vessels infiltrating the tumor (C) (n=12). 
 
4.6.4    Repetitive analysis of fpvCT images in living mice 
Non-invasive high resolution fpvCT was employed to obtain detailed characterization 
of lewis lung carcinoma mice model in vivo. The scanning revealed that lung tumors 
were closely attached to the pulmonary artery. Small tissue bridges suggested tumor 
nutrition from branches of the attached vessels (Fig. 26A, B, C, D). Both pulmonary 
arteries and veins were connected to the tumor by such bridges. This observation 
confirmed primary nutrition of the tumor from pulmonary circulation. The fpvCT 
permitted tumor detection down to a size of about 0.1 mm. 
 
 
 
Figure 26: In vivo volumetric computed tomography (fpvCT) scanning of LLC1 lung tumors. 
Documentation of a lung nodule (0.5 mm in diameters, arrow) in axial (A) and coronal (B) projections, 
imaged with fpvCT. The voxel size was 0.05 mm in an isotropic dataset. Therefore, three-dimensional  
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visualization was readily available. Panel (C) displays a surface rendering of the pulmonary arteries (PA) 
and pulmonary veins (PV) with the adjacent nodules (arrow), as well as a large tumor mass (TM) in the 
apical lobe of the right lung. Panel (D) a magnification of the nodule displayed in the reformatted slices 
(A, B) shows the bridge structure from tumor to the adjacent pulmonary artery (n=12). Arrow  indicates 
lung nodule. 
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5.    Discussion 
5.1    Therapeutic strategies 
5.1.1    HIF-1α overexpression in lung adenocarcinoma mouse model 
In the present study, overexpression of HIF-1α in adenocarcinoma A549 cells resulted 
in reduced proliferation and increased apoptosis. In line with this data, subcutaneous 
tumors derived from HIF-1α overexpressing A549 cells revealed decreased tumor 
growth and increased apoptosis, though the vascularization in these tumors was 
enhanced. These data reflect the fact that HIF-1α acts as a negative regulator of tumor 
growth in the lung adenocarcinoma model, despite a concomitant increase in 
vascularization, confirmed by both in vitro and in vivo studies.  
Reduced proliferation and increased apoptosis observed in HIF-1α overexpressing 
A549 cells correlated with preceding studies illustrating that hypoxic conditions 
induce HIF-1α dependent growth arrest and apoptosis in embryonic stem cells 
(Carmeliet et al., 1998), mouse embryonic fibroblasts (Schmaltz et al., 1998), and 
lymphocytes (Goda et al., 2003).  
Likewise, tumor growth retardation by HIF-1α overexpression in adenocarcinoma 
mouse model was also in line with a reciprocal study (Carmeliet et al., 1998) that 
analyzed a tumor model derived from embryonic stem cells with inactivated HIF-1α. 
These tumors exhibited accelerated growth despite decreased vascularization. In an 
additional study analyzing HIF-1α and HIF-2α expression in breast cancer cell lines, 
a surprising inverse correlation between low HIF-1α and HIF-2α and cells surviving 
under hypoxic conditions was observed (Blancher et al., 2000). Interestingly, these 
cell lines exhibited high basal levels of VEGF, which in turn stimulated angiogenesis 
and supported tumor growth (Ryan et al., 1997; Maxwell et al., 1997; Elson et al., 
2001).  
We believe that apoptosis induction by HIF-1α in our adenocarcinoma model could 
be mediated either by increased stability of p53 or by suppression of Bcl2 family 
member NIP3 (Bruick et al., 2000; Ravi et al., 2000). In addition, the expression level 
of p53 could negatively influence HIF-1α stabilization by interacting with HIF-1α 
ubiquitination, thereby linking a primarily apoptotic factor to angiogenesis (Bruick et 
al., 2000). Because HIF-1α can be regulated by molecules such as growth factors  
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(Fukuda et al., 2002), oncogenes (Laughner et al., 2001), and tumor suppressor genes 
(Bruick et al., 2000; Jiang et al., 2003; Zimmer et al., 2004), its cellular context 
determines its role in a specific tumor model. This phenomenon might also explain 
the ambiguity observed in clinical studies linking HIF-1α expression with patient 
survival. 
Several clinical studies, including studies involving ovarian tumors, lymph node-
negative and lymph node-positive breast carcinomas, have suggested that HIF-1α 
overexpression is independently correlated with poor patient prognosis (Birner et al., 
2001, 2002; Schindl et al., 2002). Similarly, two other studies examining cervical and 
oropharyngeal cancers also indicated that HIF-1α was an independent marker for poor 
outcome (Aebersold et al., 2001; Burri et al., 2003).  
However, in one study, lung cancer patients with high HIF-1α expressing tumors 
showed longer median survival times. This study demonstrated a role for HIF-1α in 
apoptotic induction (Volm et al., 2000). An additional study, performed on patients 
with head and neck cancers, revealed decreased tumor growth in high HIF-1α 
expressing tumors (Beasley et al., 2002). These observations are comparable with the 
experimental model described in this study and suggest that overexpression of HIF-1α 
acts as a negative regulator of tumor growth in lung adenocarcinomas.  
 
5.1.2    Therapy with hybrid primed lymphocytes and hybrid vaccination 
Fusion of C57/BL6 mice bone-marrow-derived DCs with LLC1 cells resulted in 
around 50% efficiency. Immunization with fusion cells activated proliferating and 
cytotoxic T-cells and significantly retarded tumor growth; this was also confirmed by 
upregulated expression of distinct cytokine genes. The same observations were 
supported by vaccination with fused cells in the tumor-bearing host. Finally, when T-
cells from fused-cell-vaccinated mice were transferred into naive tumor-bearing mice 
(adoptive cellular therapy), tumor growth was greatly retarded, and an efficient 
proliferative and cytotoxic T-cell response was observed. Tumor growth was reduced 
by over 50%, and tumor development was significantly delayed, suggesting an 
effective immunotherapy against poorly immunogenic carcinomas.  
We established stable hybrid cells by fusing DC with autologous LLC1 cells from 
C57/BL6 mice, as fused tumor and APC cells are believed to more efficiently induce  
 Discussion                                                                                                                    62
                                                               
 
a host T-cell mediated anti-tumor response. The underlying principle of this approach 
is the generation of single cells that encompass the antigen presentation ability of the 
parental LLC1 cell (Gong et al., 1997; Kawada et al., 2003). Accordingly, hybrid 
cells generated in the present study demonstrated the full functional potency of DCs, 
along with the co-expression of separately prestained membrane markers (PKH-67 
and PKH- 26), as evidence for efficient single cell fusion. 
Lymphocytes obtained from mice immunized with hybrids showed a slight 
proliferative response to syngeneic naive tumor cells in vitro, as well as cytotoxicity 
against LLC1 cells, without any evidence of cross-reactivity against B16/F10 tumor 
cells. Furthermore, the analysis of anti-tumor effects mediated by hybrids in 
protective immunization, vaccination, and adoptive therapy proved promising.  
In the group of mice that received immunization as a protective strategy, only hybrid- 
immunization induced partial host productivity against LLC1 tumor challenge. These 
data were in line with the enhanced proliferative and cytotoxic response of T-
lymphocytes derived from mice that received HCs and tumor cells against naive 
LLC1 tumor cells in vitro, as compared to animals that only received immunization.  
Furthermore, HC vaccination resulted in long-lasting tumor growth retardation, 
compared to the minimal effects of DC vaccination or HC immunization. This might 
have been due to the vaccination’s ability to capture tumor antigens and effectively 
present these TAA to unprimed and/or host APC-primed T-cells in vivo. This 
behavior corroborated with the vaccination-elicited activities that were CTL specific 
against LLC1 tumor cells (Yang S. et al., 1997).  
Most impressively, hybrids were also remarkably effective in the adoptive LLC1 
tumor therapy model. Adoptive transfer of HC primed T-cells was therapeutically 
effective against established tumors. The magnitude of tumor retardation was almost 
equal to the effects of vaccination with HC. In addition, increased cytotoxicity against 
naive LLC1 tumor cells by T-cells harvested from mice that had received adoptive 
treatment was observed. This finding was supported by the increased spleen sizes, 
indicating an increased population of T-lymphocytes responsible for tumor 
suppression. 
In addition, we demonstrated that the hybrid mediated cytotoxic responses were 
mainly based on CD8+ lymphocytes, although CD4+ T-cells and NK cells also 
appeared to be factors. NK cell activation mediated by hybrid cells was more likely  
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the result of an intermediate interaction of DCs with CD4+ T-cells, rather than a 
direct effect of DCs on NK cells. CD4+ T-cells acted as links between DCs and NK 
cells, possibly through the induction of host DCs, producing IL-15 via interaction of 
CD40 ligand on the T-cell and CD40 on the DC (Ge et al., 2002). In conclusion, these 
findings suggest that hybrid vaccination or adoptive transfer of hybrid-primed 
lymphocytes elicits anti-tumor immunity against tumors that are not highly 
immunogenic. 
 
5.2    Tumor imaging modalities 
 
5.2.1    Micro computed tomography (µCT) 
Our results suggest that µCT is a reliable and non-destructive method for volumetric 
quantification of intrapulmonary tumors in the mouse model. Unlike 
histomorphometric procedures, µCT permits complete quantification of the vascular 
parameters. 
µCT also allows us to visualize the architecture of tumor vasculature and, most 
importantly, to derive quantitative information from these images. The method allows 
the entire lung tumor to be studied intact, without physically sectioning or otherwise 
disrupting the tissue. However, µCT is restricted to ex vivo investigation of lung 
tumors for optimal visualization of the vasculature. Previous studies that have 
involved µCT imaging of the vasculature have used either barium sulphate-based 
contrast agents (Langheinrich et al., 2004) or polymerizing compounds containing 
lead chromate (Holdsworth et al., 2002). We found the polymerizing agent silicon-
based microfil (lead chromate based) to be far superior for the intrapulmonary tumor 
model; however, we consider both agents useful, depending upon the mode of 
application. In this study, the silicon polymer was ideal for imaging intrapulmonary 
tumors because it allowed us to circumvent problems such as settling and lack of 
homogeneity within the vasculature, clumping during injection, and difficulty with 
perfusion due to high viscosity. In addition, silicon polymer allowed us to 
differentiate pulmonary vascular tree from pulmonary arteries, thereby facilitating the 
delineation of tumor vascular origin. 
Furthermore, the adjustments that exist when defining the binarization threshold and 
the scanning resolution are important methodological aspects that must be considered  
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when using µCT imaging for analysis of tumor vasculature. The most important 
parameter is how to determine binarization thresholds in the µCT system. Luo et al. 
(1999) studied the relation between binarization thresholds and detectability of several 
structures. However, an uncertainty that varies according to the type of specimen does 
exist. As recommended by previous reports (Bentley et al., 2002), the optimal 
binarization threshold for each specimen was determined in this study. A value, based 
on the threshold that captured the complex architecture of tumor microvasculature 
with minimal overestimation of broader structures, was chosen. 
Likewise, the voxel size of the scan was also selected to image smaller vascular 
structures. For example, a voxel size of 8 µm was shown in our study to be 
appropriate for measuring a minimum vessel diameter of 9 µm, much smaller than 
any obtained by previous µCT images (Maehara et al., 2003). However, drawbacks, 
including increased scan time and computational time, as well as more complex 
analyses, did exist.  
In our study, µCT was used for volumetric quantification of a tumor and its vascular 
structures, but only structures delineated with sufficient contrast material could be 
visualized and quantified. By using tomographic reconstruction algorithms (Volume 
rendering technique), images of the vessels in the lung tumors that allowed total 
stereoscopic visualization of the three-dimensional microarchitecture of the lung 
tumors were generated. Since tomography allows convenient extraction of appropriate 
sections from the three-dimensional images, µCT also can be used to analyze and 
quantify distinct regions of interest more accurately; i.e., we were able to measure 
intrapulmonary tumors and their total vascular content. 
 In conclusion, the current study demonstrates that µCT imaging using perfused 
contrast agents provides a robust methodology for evaluation of vascular networks. 
Specifically, µCT is advantageous because it provides high resolution, quantitative, 
3D, and objective data analysis. This was evident in our validation study using 
histological images, which found µCT to offer a highly accurate, less variable and less 
time-consuming alternative for quantitative measure of intrapulmonary tumors and its 
vascular content in the LLC1 mouse model. µCT techniques also offer flexibility to 
the user in defining the volume of interest (VOI) to be evaluated. Thus, contrast-
enhanced µCT imaging provides broad applicability to tumor model systems  
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that require a vigorous and highly quantitative evaluation of vascular structure or 
growth. 
 
5.2.2    Flat panel volumetric computed tomography (fpvCT) 
The fpvCT proved its superior sensitivity in the detection of lung nodules. The 
accuracy in volumetry of nodules down to 0.2 mm in diameter was shown in 
histology. FpvCT, a new high resolution imaging system, proved its abilities in 
monitoring a lung tumor model, proving the importance of follow-up investigations in 
cancer research. 
Few reports about follow-up studies of lung disease in mice can be found in medical 
literature (Kennel et al., 2000; Ford et al., 2003; Schuster et al., 2004; Kiessling et al., 
2004; Plathow et al., 2004). Although there is a rising need for diagnostic procedures 
to investigate tumor models, the lung is difficult to assess with conventional imaging 
techniques (Mitzner et al., 2001; Schuster et al., 2004). A limiting factor is the 
susceptibility of the systems to motion artefacts. The most promising modality is 
computed tomography, offering short scanning times and satisfactory tissue resolution 
in the lung due to the high contrast between air and alveolar tissue. Short scanning 
time permits investigations in a short ventilation arrest after intubation of the animals. 
However, this is a very invasive procedure, putting the life of the animals at risk in 
repeated scanning, especially in the investigation of models with pulmonary disease. 
To avoid this situation, we attempted to investigate the animals that were breathing 
freely. As a consequence of deep anesthesia and a muscle relaxing substance, thoracic 
movement was reduced to a minimum. In fpvCT as well as in MSCT, no major 
motion artefacts impeding image evaluation were observed, though slight blurring of 
the diaphragm indicated residual movement. 
FpvCT showed a significant increase in sensitivity to small lung nodules compared to 
MSCT. Therefore, it is important to integrate fpvCT into cancer research in small 
animals to give preclinical research important information on their models. Benefits 
include (i) information about successful tumor induction, (ii) quantification of tumor 
growth, (iii) observation of possible complications (pneumonia, atelectasis), and most 
importantly, (iiii) success of therapeutic approaches. 
Beyond monitoring of lung nodules, fpvCT could be used to detect and characterize 
structural lung pathologies like emphysema or fibrosis. The option to evaluate  
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functional parameters like tumor perfusion, previously reported for other modalities in 
subcutaneous tumors (Kiessling et al., 2003; Krix et al., 2003), has been exercised. 
The feasibility of morphological imaging of angiogenesis with fpvCT has been 
demonstrated (Kiessling et al., 2004). Visualization of the vessels inside lung tumors 
is much more challenging, due to the thoracic motion and the small size of the tumors, 
although assistance of indirect parameters of angiogenesis in an orthotopic tumor 
model with perfusion imaging were available (Kerbel et al., 2004).  
In combination with other functional imaging modalities, fpvCT would help quantify 
and localize tumors. Used in combination with planar modalities like optical imaging 
(Mahmood et al., 1999; Bremer et al., 2003; Ntziachristos et al., 2003; Yang et al., 
2003) or tomographic modalities with less resolution, like PET and SPECT 
(Weissleder et al., 1998; Budinger et al., 1999; Bremer et al., 2002; Lewis et al., 
2002; Kiessling et al., 2004), fpvCT could provide helpful additional information.  
 
5.3    Applications 
 
5.3.1    Delineation of vascular supply of lung tumors 
This study describes blood flow distribution to lung tumors in an experimental 
C57/BL6 mouse model with intra-tracheal instillation of LLC1 cells. Using 
fluorescent microspheres infusions, subsequent microscopic analysis, and 3D images 
obtained by µCT and fpvCT, we identified the pulmonary artery as the major source 
of blood supply to the tumor vasculature in this model of primary lung cancer. 
Based on previous observations in nude mice, where the diameter of the capillaries 
was measured as 4-9 µm (Lehr et al., 1993; Bernard et al., 1996), we decided to use 
10 µm microspheres with different fluorescent colors. Our data revealed an average 
ratio of microspheres originating from the pulmonary to systemic systems as 13:1 
(lung) and 52:1 (tumor). These data supported the known fact that pulmonary arteries 
are the major feeding vessels of the lung parenchyma. The predominance of the 
pulmonary over systemic blood supply was markedly increased, at a ratio of 4:1, for 
the LLC1 lung tumor tissue.  
We also analyzed the microvasculature of lung tumors using µCT and fpvCT in a 
follow-up study up to one week after tumor cell seeding. 3D reconstructed images 
obtained by µCT revealed the entry and branching of the pulmonary artery in lung  
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tumors and detected capillaries as small as 9 µm in diameter. In addition, 3D images 
of the microfil-filled aorta illustrated the origin of the bronchial artery branching from 
the subclavian artery. This finding agrees with the observations of Verloop et al., who 
studied the systemic blood vessels to the lung by using casting material (Verloop et 
al., 1949). 
In agreement with the µCT data, 3D fpvCT images also revealed close attachment of 
the lung tumors to the pulmonary artery. FpvCT allowed volumetric visualization of 
small pulmonary tumors down to a diameter of ~200 µm. In addition, the 3D images 
obtained by fpvCT revealed tissue bridges connecting pulmonary vasculature to the 
nodules.  
In almost all types of cancer, tumor cells grow into solid neoplasms by using the 
host’s pre-existing vasculature, which may originate from the pulmonary or bronchial 
system, or both. However, earlier studies that employed animal models to probe the 
origin of vascularization during lung tumor growth have reported conflicting results. 
Predominant nutrient supply from both the pulmonary and bronchial systems, via 
enlarged bronchial vessels, was observed (Jonas et al., 1969; Muller et al., 1978; 
Milne et al., 1987; Bernard et al., 1996; Mitzner et al., 2000; Ley et al., 2002).  
These discrepancies might be explained in part by the tumor stage (Muller et al., 
1978), the species, the origin (primary tumor, metastasis), and the distribution 
(central, peripheral) of lung neoplasms. Milne et al. demonstrated the predominant 
perfusion of metastatic lung tumors by the pulmonary circulation in humans and rats 
(Milne et al., 1987). In contrast, in primary lung tumors using in vivo angiography, 
Jonas et al. suggested the bronchial arterial supply as the primary source of 
nourishment in dogs. However, to the best of our knowledge, vascular supply of lung 
tumors in mice has not previously been investigated. 
In our study of blood flow distribution to LLC1 primary lung tumors in C57/BL6 
mice, the pulmonary arterial system had the predominant role, although the 
bronchogenic blood supply exists in this species. Our conclusion that bronchogenic 
blood supply of lung parenchyma and tumor tissue exists in C57/BL6 mice is based 
on i) the presence of bronchogenic blood flow markers in both healthy lungs and 
LLC1 tumors, ii) the detection of fluorescent microspheres in the cryosections, iii) the 
3D-reconstruction of µCT images, which clearly demonstrated a left bronchial artery 
at the level of the main stem bronchi originating from the subclavian artery, consistent  
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with studies performed on different species (Jonas et al., 1969; Muller et al., 1978; 
Mitzner et al., 2000; Ferreira et al., 2001; Ley et al., 2002), and iv) the possibility of 
arterial anastomoses between the bronchial and pulmonary circulation, as suggested 
by our observation of systemically applied (red) microspheres, found in the 
parenchymal capillaries of the lung. 
In conclusion, this study clearly shows that the pulmonary arterial system plays the 
predominant role in the blood flow to LLC1 primary lung tumors in mice, as based on 
the analysis of fluorescent microspheres distribution and CT imaging. 
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6.    Summary 
Two mouse models of lung cancer were used to investigate cancer progression, cancer 
treatment, and cancer imaging. One model was established by subcutaneous injection 
of human adenocarcinoma A549 cells and lewis lung carcinoma (LLC1) cells, the 
other by intratracheal instillation of LLC1 cells.  
 
In the first study, the role of HIF-1 in tumor progression was investigated. 
Overexpression of HIF-1α by genetic alteration of adenocarcinoma cells decreased 
tumor size, due to decreased proliferation and increased apoptosis, despite an 
augmented vascularization observed in these tumors. 
 
In a further study, tumor regression by immunological approaches was attempted. 
Hybrids were generated by fusing dendritic cells and syngeneic poorly immunogenic 
LLC1 cells of C57/BL6 origin. Hybrid immunization induced the expression of a 
variety of cytokines and the partial host protective immunity against LLC1 tumor 
challenge. Moreover, hybrid vaccination and adoptive immunotherapy resulted in 
notable tumor regression.  
 
For establishing small animal tumor imaging in our study, three different imaging 
modalities, micro computed tomography (µCT), multi slice computed tomography 
(MSCT), and flat panel volumetric computed tomography (fpvCT) were investigated.  
 
The µCT images of intrapulmonary tumors suggested that µCT is a reliable and non-
destructive method for quantifying the volume of intrapulmonary tumors in the mouse 
model. In addition, µCT can be used to evaluate tumor angiogenesis. 
 
We exploited MSCT and fpvCT for the in vivo imaging and detection of lung nodules 
in a mouse LLC1 lung tumor model. FpvCT allowed easy monitoring of a lung tumor 
model with high resolution, facilitating follow-up investigations in cancer research. In 
addition, the superiority of fpvCT over MSCT was clearly demonstrated. 
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Furthermore, both imaging modalities (µCT and fpvCT), along with fluorescent 
microspheres, were applied to delineate the relative contribution of blood supply via 
the pulmonary and the systemic arteries to LLC1 lung tumors. All three methods 
revealed the pulmonary artery to be the primary functional source for feeding vessels 
to the lung tumors. Moreover, both modalities demonstrated the microanatomy of the 
vessels and blood-supplying tissue.  
 
The development of experimental mouse lung tumor models is essential to the 
understanding of tumor pathophysiology and vascular microanatomy. Our findings 
can be used to identify novel targets for anticancer treatment and for site specific drug 
targeting. Additionally, the successful employment of various computed tomography 
systems for lung cancer imaging in rodents offers in vivo evaluation of such 
strategies.  
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7    Zusammenfassung 
Zur Untersuchung von Tumorwachstum, Tumortherapie und Tumordarstellung 
wurden zwei verschiedene Lungentumor-Mausmodelle etabliert. Das eine Modell 
wurde durch die subkutane Injektion von menschlichen Adenokarzinom A549 Zellen 
oder Lewis-lung-karzinom zellen (LLC1), das andere durch die intratracheale 
Verabreichung von LLC1 Zellen ausgelöst. 
 
In der ersten Studie wurde die Rolle von HIF-1 auf das Tumorwachstum analysiert. 
Die genetisch verursachte Überexpression von HIF-1α in Adenokarzinom-Zellen 
führte, trotz erhöhter Gefäßbildung in den untersuchten Tumoren, über eine 
verminderte Proliferation und gesteigerte Apoptose zu einer Verminderung des 
Tumorwachstums.  
 
Eine weitere Untersuchung beschäftigte sich mit einem immunologischen Ansatz der 
Tumortherapie. Es wurden dendritische Zellen und syngene, schwach immunogene 
LLC1 Zellen, abgeleitet von C57/BL6 Mäusen, fusioniert. Immunisierung mit diesen  
Zellhybriden induzierte die Expression verschiedener Zytokine. Desweiteren wurde 
eine effektive Immunantwort gegen schwach immunogene Tumorzellen und eine 
gesteigerte T-lymphozytär vermittelte Zerstörung der Tumorzellen beobachtet. Dieser 
Effekt ließ sich sowohl durch Zellhybrid-Vakzinierung als auch durch die 
Übertragung von zuvor Zell hybrid-aktivierten T-Lymphozyten herbeiführen. 
 
Zur Darstellung der induzierten Maus-Tumore wurden die Methoden der Mikro-
Computertomographie (µCT), der Mehrschicht- Computertomographie (MSCT) und 
der Flachwandvolumen- Computertomographie (fpvCT) angewendet. 
 
Die µCT Darstellung von intrapulmonalen Tumoren erwies sich als eine geeignete, 
nicht-destruktive Methode für die Quantifizierung des Tumorvolumens. Außerdem 
war es mit µCT möglich, die Gefäßversorgung der Tumore darzustellen. 
 
Weiterhin haben wir die in vivo Darstellung und Detektion von Lungentumorknoten 
im LLC1-Lungen Modell mittels MSCT und fpvCT, untersucht. Aufgrund der 
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präzisen Bestimmung der Tumorgröße ermöglicht die fpvCT die Analyse der 
Tumorprogression in zeitlicher Abfolge. Zusätzlich konnte eine Überlegenheit der 
fpvCT gegenüber der MSCT nachgewiesen werden. 
 
In Ergänzung wurden die Methoden der µCT und fpvCT zur Detektion von 
Fluoreszenzmikropartikeln für die Differenzierung von pulmonalarteriellen und 
systemarteriellen Blutflusses hinsichtlich der Versorgung des Tumorgewebes 
eingesetzt. Der strenge Hinweis, dass die Pulmonalarterien als funktionelle Quelle der 
Lungentumorgefäßversorgung dienten, konnte von allen drei eingesetzten Methoden 
erbracht werden. Darüber hinaus war es möglich, die Mikroanatomie der Gefäße 
sowie blutversorgende Gewebsbrücken darzustellen.   
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APC    Antigen Presenting Cells 
CM    Contrast Medium 
CTLs    Cytotoxic T Lymphocytes 
CT    Computed Tomography 
DAPI    4'6-diamidino-2-phenylindole 
DC    Dendritic Cells 
DNA    Deoxy-ribo-nucleic acid 
EGFR    Epidermal Growth Factor Receptor 
fpvCT    flat panel volumetric Computed Tomography 
HC    Hybrid Cells 
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NIP3    Proapoptotic Protein 
NSCLC   Non-Small Cell Lung Cancer 
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RNA    Ribonucleic Acid  
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SCLC    Small Cell Lung Cancer 
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SEM    Standard Error of the Mean 
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Th    T-helper cells 
TM    Tumor Mass 
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